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PREFACE 
 
Prostate cancer is the second leading cause of deaths due to cancer in men in the 
United States. The American Cancer Society has projected that 192,280 new cases and 
27,360 deaths will occur in the year 2009.  Mostly, men over the age of 50 are afflicted 
by the disease and more than 70% of the men diagnosed with prostate cancer are over the 
age of 65. Most of the patients who suffer from prostate cancer do not die due to the 
tumor at the primary site but rather due to complications when the tumor has spread to 
the bone. It is estimated that each year, about 350,000 people die of bone metastasis in 
the United States. The causative tumor becomes incurable once the bone has been 
invaded and only 25% of prostate cancer patients are able to live 5 years subsequent to 
their diagnosis of bone metastasis. The interaction between prostate cancer cells and the 
bone creates a vicious cycle of bone formation and bone destruction thereby destabilizing 
the inherently delicate homeostasis within the bone. In prostate cancer, this process leads 
to metastatic lesions that are predominantly osteoblastic. However within the background 
of bone formation, several groups have reported that bone resorption is an integral part of 
prostate cancer bone lesions. Therefore, early detection and treatment before the tumor 
metastasizes is critical for the survival of the patient.  
Creating and characterizing mouse models that better mimic the progression in 
human prostate cancer is a powerful tool to study and delineate the various steps in tumor 
progression. Most of the currently available mouse models of prostate cancer successfully 
recapitulate the early steps of tumor progression in the primary site but fail to metastasize 
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to other organs especially to the bone. Amongst the existing ones, transgenic models that 
are created by dysregulating a gene that is widely known to be altered in human prostate 
cancer are considered to be more reflective of the human disease. This is in contrast to 
transgenic mouse models that overexpress the small t and large T antigens that despite the 
phenotype they produce, are considered to have little physiological significance.  
This first part of the thesis describes the creation and characterization of the 
hepsin/myc bigenic model that develops adenocarcinoma in the primary site. The second 
part of the thesis describes a model that delineates the interactions between prostate 
cancer cells and the bone microenvironment. This is approached by dysregulating the T-
box transcription factor Tbx2 in PC3 human prostate cancer cells and looking at the 
effect of this dysregulation on the interaction of the cells with the bone 
microenvironment. 
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CHAPTER I 
 
INTRODUCTION 
 
Prostate: 
The prostate is a glandular organ that surrounds the urethra at the neck of the 
bladder. It contains numerous ducts that produce secretions that contribute to the seminal 
fluid contents. In rodents, the prostate gland consists of four encapsulated and separate 
lobes: the anterior prostate (AP), dorsal prostate (DP), ventral prostate (VP) and the 
lateral prostate (LP). The rodent prostate lobes surround but do not encompass the urethra 
(Cunha et al., 1987). Anatomically, each prostate lobe is different and produces different 
secretory proteins. The dorsal and the lateral lobes are often examined collectively as the 
dorsolateral prostate (DLP) due to their proximity and anatomic size. In human prostate, 
although the defined zones are not as distinct, McNeal has described three anatomically 
distinct zones: the peripheral zone, the central zone and the transition zone (McNeal, 
1988). The peripheral zone that is considered to be homologous to the rodent dorsolateral 
prostate is the most common site of prostate cancer in humans (Price, 1963). 
Morphologically, the prostate gland consists of the epithelial and stromal cell 
compartments. The epithelial cells are arranged in two distinct and separate layers. The 
luminal epithelial cells are columnar cells that produce the prostatic secretions while the 
basal epithelial cells are flattened by morphology. In addition to these two epithelial cell 
2 
 
types, neuroendocrine cells that are rare are found in the basal cell layer. The stromal cell 
compartment consists of fibroblasts and smooth muscle cells. The epithelial and stromal 
cell compartments are thought to be dependent on each other for their survival and are 
separated by extracellular matrix proteins comprising the basement membrane. 
 
Human Prostate Cancer and its progression: 
Prostate cancer is the second leading cause of deaths due to cancer in men in the 
United States. The American Cancer Society has projected that 192,280 new cases and 
27,360 deaths will occur in the year 2009.  Mostly, men over the age of 50 are afflicted 
by the disease and more than 70% of the men diagnosed with prostate cancer are over the 
age of 65. This high rate of mortality is primarily due to metastasis of the primary tumor. 
The 5 year survival rate for men diagnosed while the disease is localized is nearly 100% 
while only 34% of the men diagnosed with metastatic prostate cancer survive beyond 5 
years. Therefore, early detection and treatment before the tumor metastasizes is critical 
for the survival of the patient. 
The advancement of prostate cancer in humans is a multi-step process progressing 
through a number of stages. Typically, following the development of prostatic 
intraepithelial neoplasia (PIN), the natural course of progression in human prostate cancer 
involves the development of adenocarcinoma with local invasion, and the final 
development of distal metastases to sites such as the bone, lung and liver.   
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Despite the prevalence of the disease, our knowledge of the genetic alterations 
occurring during prostate cancer is limited. The development of PSA screening in the 
1990’s resulted in a better diagnosis of PCa and initially the incidence of the disease 
appeared to increase dramatically. However, it is now recognized that the incidence of 
the disease has not changed over time.  Previously, when PSA screening was not the 
norm, PCa was diagnosed by clinical syndromes or by Digital Rectal Examination 
(DRE). However, in the majority of cases, these diagnostic methods were ineffective 
since the tumor had already metastasized beyond the organ. Today, PSA screening is 
routinely performed and has clearly revolutionized the clinical management of PCa. 
Though many cases today are detected by PSA levels in the 2.5-10 ng/ml range, however, 
using PSA screening for early detection of PCa has its limitations too. Since PSA is 
specific to the prostate organ rather than PCa, elevation of PSA levels can occur in other 
benign pathophysiologies of the prostate such as prostatitis, BPH, and Prostatic 
Intraepithelial Neoplasia (PIN). Therefore, serum PSA levels alone cannot differentiate 
between adenocarcinoma and other non-malignant diseases of the prostate.  
Specific morphologic changes and corresponding changes in gene expression 
occur during the progression of prostate cancer. The precancerous lesion Prostatic 
Intraepithelial Neoplasia (PIN) is widely accepted to be the precursor of prostate cancer. 
PIN is characterized by intra-acinar proliferation and the cells often display nuclear 
anaplasia. All of the morphologic changes are restricted to the epithelial compartment 
and the basement membrane is intact. The basal cells though present may have decreased 
numbers. Notably, chromosomal loss of 8p21 region occurs in 63% of PIN lesions and 
90% of prostate cancers (De Marzo et al., 2004). Two of the most notable changes during 
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this stage of the disease are the marked up-regulation of the cell-surface protease hepsin 
(Chen et al., 2003; Dhanasekaran et al., 2001; Ernst et al., 2002; Luo et al., 2001; Magee 
et al., 2001; Stamey et al., 2001; Stephan et al., 2004; Welsh et al., 2001)                      
and loss of expression of the prostate-specific homeobox protein Nkx3.1 (Bowen et al., 
2000).  
PIN progresses to adenocarcinoma and this transition is characterized by 
cytologic atypia including enlargement of nuclei and nucleoli. In addition, the basal cells 
are lost. Notably, the basement membrane is disrupted and the tumor displays local 
invasion. The organization of epithelial cells is lost progressively and the tumor changes 
from well differentiated (Gleason score 2-4), to moderately differentiated (Gleason score 
5-6) to poorly differentiated (Gleason score 8-10). A number of genetic alterations are 
linked with the transition to prostate adenocarcinoma, most notable of which are the 
inactivation of the transcription factor KLF6 (55% of primary tumors) (Narla et al., 2001) 
and loss of PTEN (10-15% of primary tumors) (Wang et al., 1998). In addition, 
amplification of the c-myc locus (8%) (Jenkins et al., 1997) and loss of the cell cycle 
regulator protein Rb (19%)(Bookstein et al., 1990; Jarrard et al., 2002) have been 
reported. Poorly differentiated prostate adenocarcinomas that have advanced to Gleason 
score 7-10 often show loss of expression of cell adhesion proteins such as E-cadherin, 
alpha catenin, KAI1, B4 integrin and basement membrane proteins laminin-332 and 
collagen VII (Dong et al., 1995; Gao et al., 1997; Nagle et al., 1995; Umbas et al., 1994). 
The roles of Myc overexpression, and inactivation of PTEN, p27 and Rb in prostate 
cancer have been demonstrated using mouse model systems (Ellwood-Yen et al., 2003; 
Maddison et al., 2004; Trotman et al., 2003). 
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The next critical step of PCa progression is the ability of the tumor cells to spread 
to distant organs through the blood and lymphatic circulation systems. This step 
represents an important hallmark of cancer progression because the primary tumor that is 
localized to the organ is curable while the tumor that has metastasized to distant organs is 
lethal. This stage is morphologically characterized by the presence of metastatic foci in 
the lymph nodes. Several genes that are thought to be associated with metastasis have 
been reported. Notably, of the tumors that have metastasized, PTEN is lost in 30-43% 
(Cairns et al., 1997) and myc is amplified in up to 21% (Jenkins et al., 1997) of the 
tumors. Additionally, over-expression of the transcription repressor EZH2 (Varambally et 
al., 2002) and constitutive upregulation of the hedgehog signaling pathway (Karhadkar et 
al., 2004) have been reported in metastatic prostate cancer.  
 
Androgen Receptor and prostate cancer progression: 
The androgens together with the androgen receptor (AR) play an important role in 
normal  prostate differentiation and prostate cancer progression (Beato, 1989; Cunha, 
1994; Cunha et al., 1987; Evans, 1988). The AR is expressed throughout the initiation 
and progression of PCa. Normal prostate epithelial cells and the majority of prostate 
adenocarcinomas require androgens for their survival. Androgen ablation remains the 
gold standard for the treatment of prostate cancer. Although the tumor initially regresses 
in response to androgen ablation, it eventually becomes hormone refractory and continues 
to grow in androgen-ablated conditions. It is believed that this hormone refractoriness is 
due to the clonal expansion of androgen insensitive cells. There is no effective treatment 
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for hormone-refractory metastatic prostate cancer which is lethal. The molecular 
mechanisms by which prostate cancer progresses from androgen dependent to androgen 
refractory state are not yet fully known.  
 
Mouse Models of prostate cancer: 
Transgenic mouse models have been long exploited and provide an excellent 
opportunity to identify genes that contribute to the development of prostate 
adenocarcinoma, with the eventual goal of to elucidating the molecular basis of targeted 
drug therapy for human prostate cancer. Developing mouse models to delineate the 
mechanisms that control tumor progression and metastasis presents a formidable 
challenge since no single model appears to reflect all the changes that occur in human 
prostate cancer. Recently, several advances have been made in the area of mouse 
engineering techniques and hence the effort is to generate a mouse model that mimics 
human cancer in as many molecular features as possible. It appears that the development 
of tumor pathology in genetically engineered mouse models for prostatic adenocarcinoma 
falls into several categories. In a few mouse models, the transgene induces epithelial 
hyperplasia combined with stromal proliferation, thereby reflecting the pathophysiology 
of benign prostatic hyperplasia (BPH). In some models, the transgene induces abnormal 
proliferation of the epithelial cells with the result of producing a few layers of epithelial 
cells known as LGPIN, similar to what is found in humans. Other models mimic human 
HGPIN in which the epithelial cells proliferate further to occupy the glandular lumen and 
display large pleiomorphic nuclei with prominent nucleoli.  Only a very limited number 
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of models develop metastasis to distant sites. Examples of metastasis models include 
those expressing both SV40 Large-T/small-t antigen genes and bigenic mouse models 
whereby two transgenic lines have been crossbred. Therefore, mouse models showing 
metastasis have been the most difficult to create. The two most important factors in the 
creation of  transgenic models are the choice of promoter to target the prostate and the 
transgene to induce the development and progression of prostate cancer.  
 
Selection of the promoter: 
Of critical importance is the choice of promoter to target the transgene to the 
tissue of interest. It was found that two different androgen receptor (AR)  binding sites, 
ARBS-1 (located at position -236 to -223) and ARBS-2 (at position -140 to -117) in the 
probasin (PB) promoter were required for maximal induction of CAT gene expression in 
response to androgens (Rennie et al., 1993). The region spanning both elements (-244 to -
96) was termed as androgen responsive region (ARR) (Kasper et al., 1994). Later, (Yan 
et al., 1997) isolated  a 12 kb fragment of the PB promoter (termed LPB) that produced 
considerably higher levels of CAT gene expression in the prostate of transgenic mice. 
The advantage of this LPB promoter was that it remained specific to the luminal cells as 
was the smaller -426/+28 bp PB promoter fragment but it targeted high levels of 
transgene expression. Subsequently, the ARR2PB promoter was developed by linking two 
ARRs to the PB promoter and was consistently efficient in driving high levels of 
transgene expression in transgenic mice (Ellwood-Yen et al., 2003; Zhang et al., 2000). 
The shorter probasin promoter (-426/+28) also specific to the prostate, drives a lower 
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level of transgene expression. The C3(1)-c-myc transgenic mouse model that is driven by 
the C3(1) promoter element primarily develops hyperplasia with dysplasia. In contrast, 
the Lo-Myc model and the Hi-Myc models driven by the PB and ARR2PB promoters, 
respectively, develop locally invasive adenocarcinoma, except that progression in the Hi-
Myc model takes half the time as compared to Lo-Myc mice (Ellwood-Yen et al., 2003). 
Therefore, promoter selection is important for driving high levels of expression that is 
sufficient to display a phenotype in the prostate.  
 
Bigenic models: 
Several mouse models demonstrate that single gene disruptions lead in most 
cases, to LGPIN and HGPIN and not adenocarcinoma nor metastatic disease. Therefore, 
a number of bigenic mouse models have been created in an effort to determine if two 
genetic hits promote the disease, leading to metastasis. If the phenotype of a single gene 
model is limited, crossbreeding with another mouse model to generate a bigenic model 
often displays greater phenotypic changes. For instance, the phenotype of p27Kip1 -/- 
and PTEN -/- mice range from mild hyperplasia to dysplasia, respectively. However, the 
bigenic model in which these two lines were crossbred (PTEN +/- x Cdkn1b -/- model) 
displays locally invasive tumors in 25% of the mice. Similarly, although the mouse 
model in which Nkx3.1 is lost displays hyperplasia and dysplasia, the bigenic model 
resulting in cross between loss of Nkx3.1 in combination with PTEN haploinsifficiency 
in PTEN +/- x Nkx3.1 -/- prostates displayed HGPIN and early carcinoma lesions (Kim 
et al., 2002). Further, mice with PTEN +/- x Nkx 3.1 -/- prostates showed increased 
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HGPIN/early carcinoma as compared to PTEN+/- X Nkx 3.1+/- prostates showing that 
the transformation rate was dependent on the number of alleles lost (Kim et al., 2002). 
Therefore bigenic models with two or three genetic hits have clearly shown that 
progression of disease in mouse models requires more than perturbation of a single gene.  
 
Prostate cancer mouse models carrying the small t and large T antigen transgenes:  
Several prostate cancer mouse models have been generated using the SV 40 
Large-T and small-t antigens. The SV40 large-T antigen acts by binding p53 (Pipas and 
Levine, 2001) and Rb (DeCaprio et al., 1988). In contrast, the small-t antigen facilitates 
cellular transformation by providing essential mitogenic signals (Asamoto et al., 2002). 
The Lady transgenic model was generated by driving the Large-T antigen (Tag) under the 
influence of the long PB promoter (LPB-Tag) to the mouse prostate (Kasper et al., 1998; 
Masumori et al., 2001). The 12T-7 line is one of the several lines obtained from this 
transgenic mouse and is the most extensively studied among the LPB-Tag transgenic 
lines. The 12T-7 line develops multifocal lesions that display groups of cells with 
eleongated hyperchromatic nuclei interspersed among normal epithelial cells. These 
lesions further progress from LGPIN to HGPIN with localized intraprostatic invasion 
(Kasper et al, 1998). These tumors were androgen dependent since the tumors regressed 
after castration and subsequent administration of androgens restored the pre-castration 
phenotype. One of the other LPB-Tag lines, the 12T-10 model displayed PIN lesions that 
progressed to neuroendocrine (NE) prostate cancer with metastases to lymph nodes, liver, 
lung spleen, kidney and occasionally to bone (Masumori et al., 2001). The occurrence of 
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bone metastases in this model was 3/21 or 14% of mice. Other models including the 
TRAMP model (Gingrich et al., 1996; Greenberg et al., 1995; Kaplan-Lefko et al., 2003), 
C3(1)-SV40 Large-T/small-t (Shibata et al., 1996a; Shibata et al., 1996b), cryptidin 2-
SV40 Large-T/small-t (Perez-Stable et al., 1996), gp91-phox-SV40 Large-T/small-t 
(Skalnik et al., 1991), PSP94-SV40 Large-T/small-t (Gabril et al., 2002) and the (-426) 
PB-Large-T/small-t transgenic rat model (Asamoto et al., 2002; Cho et al., 2003) were 
generated with the SV40 early gene coding region expressing both Large-T as well as 
small-t antigens. All these models, displayed prostate tumorigenesis and progression to 
HGPIN. Further, all the models carrying the Large-T and small-t antigen transgenes 
developed NE differentiation and NE metastases. Furthermore, another important feature 
common to models harboring the Large-T and small-t antigen is that upon castration, the 
primary tumors regress initially, however continued androgen deprivation causes the 
tumors to grow in an androgen independent manner.  In human prostate cancer, primary 
tumors that are NE in nature are very rare, however, NE differentiation is observed in a 
few foci in some prostate adenocarcinomas (di Sant'Agnese and Cockett, 1996). 
 
Extracellular matrix molecules and prostate cancer progression: 
Extracellular and cell surface proteases are believed to play an important role in 
final stages of progression of the primary tumor i.e. invasion and metastasis. It is believed 
that these proteases are involved in the cleavage of extracellular matrix proteins in turn 
facilitating tumor cells to invade the connective tissues, blood and lymph vessels and in 
the final step metastasize to distant sites (Noel et al., 1997; Quaranta and Giannelli, 2003; 
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Woodward et al., 2007). These steps are brought about by various proteases and previous 
reports have implicated matrix metalloproteases (MMPs) (Giannelli et al., 1997; 
Koshikawa et al., 2004; Pirila et al., 2003). Apart from MMPs, serine proteases have been 
reported to be involved in degrading the extracellular matrix proteins of which the type II 
transmembrane serine proteases are a special subset. While the N-terminal cytoplasmic 
domain of serine proteases associates with intracellular molecules and participates in 
signaling, the C-terminal domain is located at the cell surface and interacts with 
extracellular matrix components. Several studies have shown that hepsin, a type II 
transmembrane serine protease (TTSP), is upregulated at both the mRNA and protein 
levels in more than 90% of human prostate cancers. For example, one study reported that 
hepsin is up-regulated by 34 fold in Gleason grades 4 and 5 (Landers et al., 2005; 
Stephan et al., 2004). Hepsin levels have been correlated positively with disease 
aggressiveness with highest hepsin expression levels present in tumors of Gleason grade 
4/5 (Xuan et al., 2006). This suggests a role for hepsin in aggressive prostate cancers. 
 
The PB-Hepsin transgenic mice: 
The construct utilized for making the PB-hepsin transgenic mice contained the 
modified probasin promoter ARR2PB, the b globin intron, full length mouse hepsin Cdna, 
internal ribosome entrance site (IRES) and humanized renilla GFP (hrGFP) cDNA 
sequence. This configuration of the transgene drives the expression of hepsin and hrGFP 
from the same transcript and thus specificity of transcription can be monitored by 
expression of GFP. Histologically, the 3-4 month old PB-hepsin mice did not show any 
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obvious abnormalities of the prostate gland, but in contrast the one year old mice 
displayed separation between the layers of epithelial cells and stromal cells. It was 
observed that these areas of separation corresponded with epithelial cells that expressed 
the greatest levels of hepsin. Since the basement membrane separates the epithelial and 
stromal layers in the prostate, the authors analyzed two basement membrane markers, 
Laminin-332 and Collagen IV. While Laminin-332 staining appeared as a continuous line 
in the wild type mice separating the epithelial and stromal cell layers, in contrast, 
Laminin-332 staining appeared weak or completely absent in the PB-Hepsin mice. 
Further, Collagen IV staining revealed a diffused localization in the PB-hepsin mice. In 
addition, the staining of α6β4 integrin, a major basement membrane receptor that is lost 
in human prostate cancers (Bonkhoff, 1998; Davis et al., 2001), was observed as a 
discontinuous line in the PB-hepsin mice in contrast to a continuous line in the wild type 
littermates.  In summary, staining with markers for the basement membrane and 
structures of cell-substratum adhesion proteins indicated that the basement membrane 
structure is severely compromised in the PB-hepsin transgenic mice. Further 
investigation of the PB-hepsin transgenic mice revealed that the prostate undergoes 
normal differentiation, proliferation and apoptosis. 
 
The PB-hepsin-12T-7f bigenic mouse model of prostate cancer: 
The hepsin mediated disruption of the basement membrane in the PB-hepsin 
transgenic mice is of interest since in human prostate cancer progression, the basement 
membrane gets disrupted during the progression from localized primary tumor to 
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invasive metastasizing cancer (Abate-Shen and Shen, 2000). To investigate the role 
played by hepsin expression in prostate cancer, the hepsin transgenic mice were crossed 
with the LPB-Tag line12-T7f. The prostates of the 12T-7f transgenic line display massive 
enlargement of the prostate, develop high grade PIN and limited foci of adenocarcinoma 
by 20 weeks, but do not display any metastases. Examination of the PB-hepsin-12T-7f 
bigenic mice at 21 weeks displayed adenocarcinoma with half of the mice showing 
histological features of rosette formation indicating neuroendocrine differentiation. 
Immunohistochemical staining with the proliferation marker Ki67 showed no differences 
in cell proliferation between the LPB-Tag and the LPB-Tag/PB-Hepsin mice. However, 
the bigenic mice displayed increased apoptosis as indicated by TUNEL staining. 
Interestingly, immunofluorescent staining with antibodies that recognize extracellular 
matrix proteins revealed that that collagen IV staining was severely reduced in the LPB-
Tag/PB-Hepsin mice, also beta4 integrin revealed disorganized basement membrane in 
the double transgenic animals. These changes in the staining pattern of basement 
membrane proteins in the bigenic mice indicate hepsin mediated disruption of the 
basement membrane. More importantly, by 21 weeks of age, 24% of the bigenic LPB-
Tag/PB-hepsin mice developed metastases to liver, lung and bone. Notably, these 
numbers could be an underestimation since only the femur bones which represent only a 
small fraction of total bone mass was analyzed in the study. These metastatic lesions 
contained tightly packed cells that show morphologic features of NE differentiation of 
nuclear molding and high nuclear/cytoplasmic ratio. Further, these lesions, akin to 
metastatic lesions in other SV40 T antigen driven mouse models including TRAMP, 
CR2-T-Ag and LPB-Tag line 12-T10 stained positively for synaptophysin confirming 
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their NE phenotype. It is possible that these metastatic lesions are either NE in origin or 
that they undergo transdifferentiation from epithelial to NE cell type during the process 
of metastasis. Although the metastatic lesions in the hepsin bigenic mice are NE in 
nature, it still is one of the very few models that develop bone metastasis. Bone 
metastasis is a very important feature in prostate cancer mouse models since human 
prostate cancer preferentially metastasizes to bone and the mechanisms responsible for 
bone metastasis are largely unknown. Interestingly, while the bone metastases in human 
prostate cancer are predominantly osteoblastic, in the bone lesions in LPB-Tag/PB-
Hepsin mice no obvious osteoblastic or osteolytic characteristics were detected.  
 
The PB-Myc model: 
Multiple studies in human prostate cancer have shown increased Myc gene copy 
number in up to 30% of tumors including PIN lesions (Fleming et al., 1986; Jenkins et 
al., 1997; Nesbit et al., 1999; Qian et al., 1997; Sato et al., 1999). However, this 
observation is not conclusive since Myc is one of the many genes located in the 8q24 
amplicon (Elo and Visakorpi, 2001). Several studies have shown that the mechanism by 
which Myc induces cancer is due to its effect of increased cell proliferation thus 
contributing to tumorigenesis. In contrast, several studies have also documented the pro-
apoptotic activity of Myc, particularly in conditions of limiting survival factors or low 
serum. (Ahmed et al., 1997; Pelengaris et al., 2002b; Prendergast, 1999).  Further, these 
findings are in agreement with several transgenic mouse models expressing Myc that 
have demonstrated that the response to Myc expression is critically dependent on the 
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associated survival signals (Pelengaris et al., 2002a; Pelengaris et al., 2002b). To study 
the effect of increased Myc expression in mouse prostate, human c-Myc was expressed 
from two different strength prostate-specific probasin promoters, (-426/+28) probasin-
Myc and ARR2/probasin-Myc and the transgenic Myc mice were termed as Lo-Myc and 
Hi-Myc mice respectively. The probasin gene starts to express at a low level in the mouse 
prostate at 1-2 weeks of age and expression increases as androgen levels increase 
between 4 and 8 weeks of age. The ARR2PB probasin is the stronger promoter since it 
contains two additional androgen response elements thus increasing the androgen 
dependent expression (Wu et al., 2001b; Zhang et al., 2000). While the Lo-Myc mice 
developed PIN lesions at 4 weeks, the Hi-Myc mice displayed PIN lesions at 2 weeks. 
Transition from PIN to invasive cancer was evident in Lo-Myc mice after 1 year while 
the Hi-Myc mice displayed faster progression with invasive adenocarcinoma after 6 
months. This suggested that the dosage of Myc is directly related to the rate of cancer 
progression. Ki67 and TUNEL staining showed an increase in both proliferation and 
apoptosis as the tumor progressed from PIN to invasive cancer. The PIN lesions and 
adenocarcinoma lesions in both Lo-Myc and Hi-Myc mice did not display morphologic 
features of neuroendocrine differentiation and were negative for synaptophysin staining. 
 
Laminin-332, a component of the basement membrane (BM) is a substrate of 
hepsin: 
Laminin-332 (previously known as Laminin-5) is an Extracellular Matrix (ECM) 
molecule and is an important component of the basement membrane that separates the 
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epithelial and stromal compartments (Rousselle et al., 1991). It is a glycoprotein 
consisting of three polypeptide chains α3, β3 and γ2 that are linked by disulfide bonds 
(Aumailley et al., 2005). Laminin-332 has been reported to play critical roles in 
development, wound healing and tumorigenesis (Ryan et al., 1996). Although Laminin-
332 is over-expressed in several tumor types including oral, cutaneous, esophageal, 
colon, laryngeal, tracheal and cervical cancers (Marinkovich, 2007), interestingly it has 
been reported to be lost in prostate cancer (Calaluce et al., 2001; Davis et al., 2001; Hao 
et al., 2001). It has been reported that Laminin-332 is cleaved by several matrix 
metalloproteases (MMPs) that resulted in increased cell migration(Giannelli et al., 1997; 
Koshikawa et al., 2004).  Interestingly, the hepsin transgenic model demonstrated 
disorganized basement membrane; however, the mechanism involved in this 
disorganization was not revealed. It was reported that the hepsin transgenic mice 
exhibited weaker immunohistochemical staining of Laminin-332 as compared to wild 
type mice. In a recent study, it was reported that hepsin directly cleaves the b3 chain of 
Laminin-332 (Tripathi et al., 2008). The authors also reported that hepsin-cleaved 
Laminin-332 enhanced the motility of DU145 prostate cancer cells, thus postulating that 
direct cleavage of Laminin-332 may be one mechanism by which hepsin promotes 
prostate tumor progression and metastasis, possibly by up-regulating prostate cancer cell 
motility (Tripathi et al., 2008). 
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Bone metastasis in prostate cancer: 
The incidence of prostate cancer has consistently risen in the recent years and the 
disease is the cause of more gender-specific deaths due to cancer than any other cancer.  
About 1 in 5 men will be diagnosed with prostate cancer during the lifetime, and 1 in 33 
will die of the disease.  The morbidity and mortality in prostate cancer patients can 
almost universally be attributed due to metastasis to distant sites, predominantly the bone. 
The disease is curable when it is confined to the prostate gland but so far, efforts at 
treatment and cure of metastatic disease have met with limited success. About 80%  of 
patients who have succumbed to advanced hormone refractory prostate cancer have 
clinical evidence of metastases to the bone and histologically, 100% have bone 
involvement (Bubendorf et al., 2000; Roudier et al., 2003; Saitoh et al., 1984). It has been 
reported that bone is the predominant site of metastases for prostate cancer followed by 
breast cancer.  
As with all cancers, in order to form metastases in bone, prostate cancer cells 
must first detach from the epithelial tissue by and invade surrounding tissue producing 
proteolytic enzymes. The epithelial cells must invade the adjacent stromal compartment, 
penetrate the basement membrane and endothelial cell layer and enter the blood 
circulation (Liotta and Kohn, 2001). The cells then travel to distant organ sites, most 
notably bone in the case of prostate cancer. This series of initial events has been 
described as inefficient and therefore many cancer cells do not survive and get past the 
protective host-surveillance mechanisms (Fidler, 1978; Liotta and Kohn, 1990; Zetter, 
1990). The prostate cancer cells that have survived enter the wide-chanelled sinusoids of 
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the bone marrow cavity, adhere to the extracellular matrix, proliferate and form new 
blood vessels.  
Although the mechanisms of the metastatic process to the bone are poorly 
understood, the widely believed mechanism is the seed and soil hypothesis first proposed 
by Steven Paget more than 100 years ago. Paget’s theory of metastasis proposes that the 
tumor cells (seed) find a suitable environment (soil) and so the migration of tumor cells 
to bone may be a result of the adhesion and growth properties of the tumor cells. (Fidler, 
2003). Another theory proposed by Jacob et al suggests that specific homing factors in 
the bone facilitate the migration of cancer cells to the bone (Jacob et al., 1999). Several 
studies have shown that specific growth factors in bone can support and facilitate the 
growth of prostate cancer cells (Chackal-Roy et al., 1989; Gleave et al., 1991). Bone 
marrow, the site where cancer cells invade is a rich bed of growth factors and cytokines 
that promote the growth of tumor cells. Additionally, the bone is rich in transforming 
growth factor-β (TGFβ) and Insulin-like growth factor (IGF)-1 that stimulate the 
invading tumor cells. 
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Figure 1: Steps involved in the metastasis of tumor cells from the primary tumor to 
the bone. (From Mundy GR, Nature Reviews Cancer, 2002, 2: 584-593) 
 
Prostate cancer metastases are predominantly osteoblastic in nature: 
Traditionally, bone metastases have been classified as either osteolytic or 
osteoblastic. It is believed that osteolytic lesions are a result of osteoclast-activating 
factors. These factors are released by the tumor cells in the bone microenvironment and 
parathyroid-hormone-related peptide (PTHrP) is the most notable of these factors. 
Conversely, osteoblastic lesions are thought to be caused by cancer cells that activate 
osteoblast proliferation and differentiation with resulting bone formation. It has now been 
realized in the field of bone biology that these two lesion types are the two extremes – 
morphological analyses of bone metastatic lesions in patients has shown that bone lesions 
are composed of both osteoblastic and osteolytic components. 
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  The metastatic lesions in prostate cancer are caused due to a complex interaction 
between the tumor cells themselves and the bone microenvironment, resulting in the 
induction of a mixture of osteolytic and osteoblastic lesions, but predominantly the 
lesions are osteoblastic in nature. Human prostatic adenocarcinoma resulted in 
osteoblastic lesions in the bone in approximately 90% of cases (Autzen et al., 1998). The 
evidence for increased bone formation in human prostate cancer metastases arises from a 
number of sources. Firstly, nuclear bone scans in addition to X-rays have frequently 
displayed extensive osteoblastic activity and this has been confirmed quantitatively by 
bone histomorphometry. Bone biopsies in several prostate cancer patients having 
advanced disease have thus shown increases in osteoid surface and in osteoid volume, 
whereas this has not been observed in biopsies from prostate carcinoma patients having 
localized tumors (Clarke et al., 1993).   This new formation of bone was associated with 
an increase in the mineral apposition rate therefore implying the formation of mineralized 
new bone. Further, histologic observations have shown an increase in woven bone that is 
associated with metastatic prostate carcinoma showing the presence of multiple 
osteoblast cells adjacent to the tumor tissue-bone interface. Osteoblastic metastases can 
potentially cause hypocalcemia and cause pathologic fractures as the newly woven bone 
is intrinsically of low strength (Szentirmai et al., 1995). The osteoblastic metastases lack 
a suitable mouse model and information about these lesions is limited to studies of human 
prostate cancer patient specimens. The pathophysiology of osteoblastic and osteolytic 
lesions of bone metastases involves interactions between tumor cells, osteoblasts, 
osteoclasts, endothelial cells, fibroblasts, bone marrow precursor cells and cells of the 
immune system.  
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Figure 2: Mechanistic model of osteoblastic metastases and bone formation in 
human prostate cancer. (From Mundy GR, Nature Reviews Cancer, 2002, 2: 584-593) 
 
Mechanisms of osteoblastic metastasis: 
There is now evidence that multiple factors stimulate bone formation that is 
associated with osteoblastic lesions. Among them, endothelin-1, a ubiquitous growth 
factor has been reported to activate osteoblast proliferation and bone formation in bone 
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organ cultures. Patients with advanced hormone refractory prostate cancer with 
metastatic lesions were found to have significantly higher plasma concentrations of 
endothelin-1 as compared to patients without metastases or normal controls. Further, 
expression of endothelin-1 is increased in breast cancer cell lines that produce 
osteoblastic metastases (Nelson et al., 1995). Endothelin-A-receptor antagonists have 
been shown to inhibit both osteoblast proliferation and bone metastases (Yin et al., 2003). 
The following are the factors thought to play a role as mediators of osteoblastic 
metastases in prostate cancer 
The transforming growth factor-β family: Several members of the transforming growth 
factor-β family have been reported to stimulate the proliferation of osteoblasts in vitro 
and new bone formation in vivo (Marcelli et al., 1990). TGF-β is highly expressed by 
differentiated osteoclasts and osteoblasts, presnt in the bone matrix and is released in its 
active form in bone resorption as a result of osteoclasts. Although TGF-β has been 
reported to play a role in osteoblastic metastases, it could also mediate osteolytic 
metastases under certain circumstances. It has been reported that TGF-β induces PTHrP 
activity (Guise, 2000). PC3 human prostate cancer cells express high levels of TGF-β2 
which is known to support bone formation in vivo. Several bone morphogenic proteins 
(BMPs) that belong to the TGF-β superfamily are expressed in both normal and 
neoplastic human prostate tissue – namely, BMP2, BMP3, BMP4 and BMP6 (Harris et 
al., 1994a). 
Proteases: It is known that proteases that activate growth factors like TGF-β play 
important roles in the bone (Dallas et al., 1995; Dallas et al., 1994). Urokinase or urinary 
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plasminogen activator (uPA) is a protease that has been implicated in processes such as 
embryo implantation, wound healing and extracellular matrix breakdown thus facilitating 
invasion of the tumor. It has been shown that overexpression of uPA in rat prostate 
cancer cells results in the induction of bone metastases in vivo (Achbarou et al., 1994). It 
was reported that the amino-terminal fragment of uPA has mitotic activity for osteoblasts 
and that its carboxy-terminal domain that has the proteolytic activity may mediate 
invasiveness of the tumor or the activation of growth factors (Rabbani et al., 1992). It is 
possible that uPA acts by cleaving plasmin, the latent TGF-β binding protein that masks 
TGF-β activity and thereby prevents the sequestration of TGF-β. Another potential 
mechanism of metastasis of prostate cancer cells is related to a serine protease, prostate 
specific antigen (PSA) that is produced in excess by prostate cancer cells and is widely 
used as a marker of tumor burden. It has been reported that PSA cleaves PTHrP at the 
amino terminus and has the potential to activate other growth factors produced by 
prostate cancer cells (Cramer et al., 1996; Iwamura et al., 1996). Though not known, a 
possible mechanism is that PSA cleaves osteoclast-stimulating growth factors such as 
insulin-growth factor-1 (IGF-1) and TGF-β and thereby activating them. 
Growth Factors: Prostate cancer cells have been reported to express fibroblast growth 
factors (FGFs) that are thought to mediate the proliferation of osteoblasts in prostate 
cancer patients (Canalis et al., 1988; Canalis et al., 1987; Dunstan et al., 1999; Izbicka et 
al., 1996; Mansson et al., 1989; Matuo et al., 1987; Mayahara et al., 1993). PDGF-BB has 
also been shown to as a potential mediator of osteoblastic response (Yi et al., 2002). In 
addition, data has shown that prostate cancer cells produce bone morphogenic proteins 
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(BMPs) and also express BMP receptors, thus indicating a potential autocrine role 
(Bentley et al., 1992; Harris et al., 1994b; Ide et al., 1997). 
 
Therapeutic approaches to minimize or reverse the osteoblastic response:  
The bone morphogenic proteins are members of the transforming growth factor-β 
superfamily that are known to be important for skeletal development and have been 
reported to induce osteogenesis (Hogan, 1996; Reddi, 1998). It is believed that BMPs 
play a major role in the osteoblastic response of prostate cancer cells. This is because 
prostate cancer cells express BMPs and their receptors, which on binding to the ligand 
promote SMAD1 signaling and over-express osteoprotegerin, an inhibitor for the 
production of osteoclasts (Brubaker et al., 2004). Further, there have been recent reports 
that BMP2 and BMP6 stimulate the invasive potential of prostate cancer cells (Dai et al., 
2005). It is therefore thought that one therapeutic approach to inhibit osteogenesis is 
through the use of BMP inhibitors. Interestingly, noggin which acts as a BMP inhibitor 
has been shown diminish the growth of prostate cancer cells in the bone (Feeley et al., 
2006). In addition, noggin has been shown to inhibit the effects of BMP6 in vitro on 
human prostate cancer cells (Haudenschild et al., 2004). These reports lend support to the 
hypothesis that one approach towards the management of prostate cancer bone metastases 
would be through the use of BMP inhibitors. 
The Wnts are a large family of proteins that are produces by prostate cancer cells 
and play a role in bone formation. The canonical Wnt pathway that acts through two 
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interacting receptors, frizzled and LRP5/6, results in the nuclear localization of β-catenin 
which in turn regulates a largely unknown set of genes that mediate bone formation 
(Westendorf et al., 2004). Dickkopf-1 has been reported to inhibit Wnt activity (Kawano 
and Kypta, 2003). In a recent report, it was shown that Wnt signaling is important in 
inducing bone formation (Hall et al., 2005). They showed that the inhibition of dickkopf-
1 changed the normally highly osteolytic PC3 cells to an osteoblastic cell line. Further, 
they showed that by over-expressing dickkopf-1 in the C4-2B cells, which normally 
produce a mixed osteolytic-osteoblastic lesions when injected into mouse tibia, turned 
C4-2B cells into osteolytic lesions. This report is the first direct in vivo study showing the 
role played by Wnt in prostate cancer bone metastasis. It is speculated that in the future, 
inhibitors of Wnt signaling will be used in prostate cancer models of bone metastasis. 
The first clinical trial to specifically target osteoblasts in prostate cancer patients 
who have bone metastases are based on antagonists to endothelin-A receptor.     
Endothelin-1 is a powerful vasoconstrictor, levels of which are elevated in patients with 
advanced prostate cancer (Nelson et al., 1995). Further, endothelin-1 has been reported to 
play a role in stimulating osteoblasts (Takuwa et al., 1989; Yanagisawa et al., 1988). The 
administration of endothelin-A receptor antagonists (ABT-627) in preclinical animal 
models reduced the number of metastatic lesions caused by endothelin-1 over-expressing 
xenografts of breast cancer (Nelson et al., 1995; Yin et al., 2003). In addition, several 
other studies have validated the important role played by endothelin axis in the induction 
of osteoblastic response (Fizazi et al., 2003; Guise and Mohammad, 2004). Atrasentan 
(trade name for ABT-627) is being used in clinical trials and has been reported to be well 
tolerated and to delay the progression of hormone refractory prostate cancer in some men 
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(Carducci et al., 2002; Carducci et al., 2003; Zonnenberg et al., 2003). Further, 
Atrasentan has been reported to significantly attenuate the blood levels of PSA as well as 
alkaline phosphatase, a marker of bone formation, suggesting that it effects both tumor 
cells and osteoblasts (Nelson et al., 2003).  
 
Therapeutic approaches to minimize or reverse the osteolytic response:  
The fact that bone metastases in prostate cancer have an osteolytic as well as 
osteoblastic component has been appreciated only in the recent years. There have been 
several reports of increased biochemical markers of osteolysis that depict bone resorption 
in prostate cancer patients (Berruti et al., 2005; Brown et al., 2005; Fukumitsu et al., 
2003; Lipton et al., 2001; Noguchi et al., 2003; Petrioli et al., 2004). These markers 
include the N-telopeptide of type 1 collagen, the pyridinoline-cross peptides and 
deoxypyridinoline-cross lined peptides. However, there have been mixed reports as to the 
efficacy of these markers in comparison to PSA in the detection of osteoblastic 
metastases and in the monitoring the progression of the tumor (Fukumitsu et al., 2003; 
Noguchi et al., 2003).  
It is thought that prostate cancer patients with bone metastases suffer from three 
processes or insults that result in decreased bone density. First, older men have decreased 
hormone levels that is thought to be critical in maintaining the bone remodeling system in 
a balanced state (Riggs et al., 1998; Stege, 2000). Though this process of bone resorption 
is slower than experienced by menopausal women, however, it is apparent clinically. 
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Secondly, androgen deprivation therapy results in additional loss of bone in prostate 
cancer patients and can exceed the bone loss encountered in early-stage menopausal 
women (Eastell, 1998; Higano et al., 2004; Smith et al., 2003). The third insult is as a 
result of factors produced by prostate cancer cells within the bone microenvironment that 
promote osteolysis. These factors include interleulin-1, interleukin-6, interleukin-11, 
parathyroid hormone related protein and RANKL (Keller and Brown, 2004; Roodman, 
2004). Apart from the morbidity experienced by prostate cancer patients due to these 
osteolytic events, bone lysis in turn releases a slew of growth factors that are present in 
the bone matrix. These factors are known to stimulate the growth of prostate cancer cells 
and thus constitute a vicious cycle of bone remodeling (Clines and Guise, 2005). 
Therefore, to reduce the osteolytic onslaught, two approaches that are complimentary to 
each other have been used. The first involves bisphosphonates that reduce the 
degradation of bone and the other approach makes use of the inhibition of the 
OPG/RANK/RANKL system. 
Bisphosphonates: Bisphosphonates are pyrophosphate analogues that have been reported 
to affect osteoclasts by several mechanisms (Rogers et al., 1997). Further, multiple 
investigations have reported that bisphosphonates have anti-tumor effects (Aparicio et al., 
1998; Hiraga et al., 2001; Shipman et al., 1998; Tassone et al., 2003) and that 
administration of zoledronic acid, a new generation bisphosphonate, effects prostate 
cancer (Lee et al., 2001; Oades et al., 2003). In a recent report, it was found that 
zoledronic acid inhibited the growth of prostate cancer xenografts when implanted in the 
tibia of severe combined immunodeficient mice (Corey et al., 2003). The study revealed 
that zoledronic acid prevented the growth of these tumors if administered in either way – 
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as a preventative or as a method of treatment after the tumor had established growth. It 
was further especially noted in the study that bisphosphonate significantly affected the 
growth of prostate cancer xenografts that were osteoblastic in nature.  
A number of clinical trials on hormone refractory prostate cancer patients with 
metastases have been performed (Ernst et al., 2003; Saad et al., 2002; Small et al., 2003). 
Several investigators have recently reviewed  the use of bisphosphonates in prostate 
cancer patients (Brown et al., 2004; Green, 2005; Higano, 2003; Pinski and Dorff, 2005; 
Smith and Nelson, 2005). Of all the clinical trials, the Zometa 039 study is the only trial 
that showed promising results of reducing the skeletal metastases including morbidity 
from pain. However, overall, it is thought that bisphosphonates have undoubtedly 
benefited in reducing the loss of bone density in aging men and that it will have a 
significant role in the treatment of prostate cancer metastases. Another approach that 
investigators are pursuing in pre-clinical models of prostate cancer is combinational 
therapy whereby both the bone as well as tumor microenvironments are being targeted 
(Bertelli et al., 2006; Efstathiou et al., 2005; Vordos et al., 2004; Witters et al., 2003). 
Fc-OPG: OPG acts as a soluble decoy receptor for RANKL and represses the 
differentiation of osteoclasts through the mechanism of RANK/RANKL interaction. It 
has therefore been surmised that in theory, OPG could be a treatment option for 
osteolytic bone lesions. Reports of preclinical studies have shown that OPG has an effect 
on prostate cancer cells growing in the bone microenvironment (Corey et al., 2005; 
Kiefer et al., 2004; Quinn et al., 2005; Yonou et al., 2003; Zhang et al., 2001). These 
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studies have revealed that OPG has its effect on the growth of prostate cancer cells in the 
bone microenvironment through the suppression of osteolysis. 
Monoclonal antibodies to RANKL and soluble RANK Fc: One of the potential 
disadvantages of using OPG to effect prostate cancer bone metastases is that OPG acts as 
a survival factor by binding to the tumor necrosis factor-related apoptosis inducing ligand 
(Corey et al., 2005; Holen et al., 2002; Shipman and Croucher, 2003). Therefore to avoid 
this drawback, investigators have been using soluble RANK-Fc and monoclonal 
antibodies to RANKL in order to block RANK-RANKL interaction (Bekker et al., 2004; 
Sordillo and Pearse, 2003). In a report using a preclinical prostate cancer model, Zhang et 
al showed that soluble RANK-Fc reduced the tumor-induced osteoblastic lesions along 
with a reduction in the markers of bone resorption and serum PSA. (Zhang et al., 2003). 
Another report showed that administration of AMG-162, a human monoclonal antibody 
to RANKL resulted in a significant decrease in markers of osteolysis (Bekker et al., 
2004). 
 
Targeting senescence pathways in cancer:  
Senescence or irreversible proliferation arrest has recently been recognized as a 
drug responsive strategy that has the potential to influence the outcome of cancer therapy. 
Chemotherapy has been used to treat cancer for decades. However, treatment strategies 
that use high drug doses are often associated with toxic side effects. Similarly low doses 
of drugs are not very effective due to patient relapse and drug resistance. It has been 
30 
 
shown that low doses of drugs can induce senescence as opposed to high concentration of 
drugs that are required for apoptotic cell death. Hence a better approach for treatment 
would be to force cells to undergo senescence since much less concentration of drug is 
required for induction of proliferation arrest (Chang et al., 2002; Schmitt, 2003; Zheng et 
al., 2004).  A good understanding of the strategies by which cancer cells can be forced 
into senescence can prove to be very useful for cancer therapy particularly due to the 
drug resistance issue. 
 
The T-box gene family:  
The T-box family genes comprises of a family of DNA binding transcription 
factors that are evolutionarily and molecularly linked by the presence of a conserved 
DNA-binding motif known as the T-box (Papaioannou, 2001)The T-box genes have been 
found in all metazoans, ranging from hydra to humans and are conspicuous for the key 
roles they play during embryonic development (Adell et al., 2003; Papaioannou, 2001; 
Showell et al., 2004) Several observations suggest that T-box genes perform important 
developmental functions.  First, the expression of most of T-box genes is specific during 
the window of embryonic development. Secondly, genetic developmental diseases in 
humans are known to be caused by mutations in several T-box genes. Thirdly, studies in 
mice achieved by targeting mutations in T-box genes have found severe developmental 
phenotypes that mimic human disorders (Chapman and Papaioannou, 1998; Naiche and 
Papaioannou, 2003).  The vertebrate genome has at least 18 different T-box genes with 
diverse functions. The T-box genes comprise of a number of subfamilies that are 
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arranged based on studies of phylogeny and expression. The Tbx2 subfamily consists of 
two pairs of linked genes which are thought to be a product of two-gene clusters (Agulnik 
et al., 1996). As a result, in humans, Tbx2 and Tbx4 cluster on chromosome 17q23 and 
Tbx3 and Tbx5 cluster on chromosome 12q24 (Agulnik et al., 1996). However, Tbx2 on 
17q23 has more homology to Tbx3 whereas Tbx4 has greatly related to Tbx5. The T-box 
proteins interact as monomers or dimmers and bind to the brachyury response element 
(TTT(G/C)ACACCTAGGTGTGAAA) (Kispert and Herrmann, 1993). Of all the T-box 
genes, Tbx2 and Tbx3 are the only T-box factors that are known to function as 
transcriptional repressors (Carreira et al., 1998; He et al., 1999). This activity is known to 
be performed by both the N- and C-terminal repression domains in Tbx2 (Paxton et al., 
2002). 
 
 Tbx2 can suppress p19(Arf) and p21 to promote immortalization:  
The Arf/Mdm2/p53 pathway is one of the best known mechanisms in the cell for 
senescence downregulation (Lowe and Sherr, 2003). A number of oncogenes or mitotic 
signals can enhance the expression of alternate reading frame (Arf) that causes the 
binding of Mdm2, p53 stabilization, and the resulting expression of p53 target genes. 
This pathway can act as a precursor of oncogenic transformation in primary cells with the 
resultant induction of p53–dependent senescence or apoptosis. Alternatively, cell cycle 
arrest can be p53 independent too.  On the other hand, silencing or inhibition of Arf can 
also lead to the same result i.e. bypass of senescence, proliferation, failure to cause 
apoptosis and immortalization of cells. Jacobs et al. reported on a genetic screen to 
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identify genes that are responsible for inhibiting senescence which showed that Tbx2 
promoted the bypass of senescence through the inhibition of p19(Arf) (Jacobs et al., 
2000). They found that this inhibition was at the transcriptional level. Further, Tbx2 
could promote the bypass of senescence in mouse embryonic fibroblasts (MEFs) that 
were predisposed to senescence. In the same study, over-expression of endogenous 
p19(Arf) in MEFs expressing Tbx2 resulted in senescence. This showed that p19(Arf) 
acts downstream of Tbx2 and that Tbx2 can control the bypass of senescence by 
negatively regulating p19(Arf). It has been shown that in primary cells, overexpression of 
oncogenes such as c-myc or activated Ras can promote senescence by activating p19(Arf) 
expression. The cells use this strategy to sense uncontrolled activation of mitogenic 
signaling pathways thereby promoting p53-dependent cell cycle arrest. Enhanced 
expression of Tbx2 can help promote the transformation event by downregulating the 
p19(Arf)-dependent pathway that would otherwise prevent abnormal myc or Ras 
expression from promoting transformation (Jacobs et al., 2000). Similar to p19(Arf), the 
p21(Waf1) cyclin-dependent kinase inhibitor
 
plays a key role in senescence and in cell 
cycle arrest after
 
DNA damage (Bendjennat et al., 2003; Gartel et al., 1996). The most 
described signaling pathway for chemotherapeutic agent-induced induction of 
proliferative arrests is initiated by DNA damage. In response to DNA damage, cell cycle 
is arrested and this effect is mediated through checkpoints which allow repair before the 
start of the next cell cycle. The stabilization of p53 leading to enhanced transcription of 
p21(Waf1) is the most important event for drug induced G1-S checkpoint leading to 
senescence. Approaches leading to both suppression and over-expression of p21 have 
resulted in increased sensitivity of cancer cells to genotypic stress leading to senescence. 
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Expression of p21 is regulated by both p53 dependent (el-Deiry et al., 1994) and 
independent pathways (Roninson, 2002). But the ability of p21 to enhance cellular 
response to drugs is usually independent of p53 status. It has been shown that ectopic 
expression of p21(Waf1) sensitized hepatoma cell line Hep 3B (p53 null cell line) to 
cisplatin (Qin and Ng, 2001).  
In another study, p21(Waf1) sensitized human non small cell carcinoma H1299 
(p53 null) and colon carcinoma DLD-1 (p53 mutant) cell lines to all transretinoic acid 
(Teraishi et al., 2003). p21(Waf1) also facilitated drug induced cell death in cells with 
functional p53 (De Schepper et al., 2003). In light of p21’s role in the mediation of drug-
induced senescence, one possible strategy to induce senescence is through the inhibition 
of genes that negatively regulate p21. It has been shown that Tbx2 can bind and repress 
the p21 promoter in vitro and
 
in vivo. Small interfering RNA-mediated down-regulation
 
of Tbx2 expression resulted in a robust activation of p21 expression (Prince et al., 2004). 
 
Tbx2 and cancer:   
It is now known that genes and signaling pathways that play important roles 
during development are dysregulated in cancer and may cause tumor initiation or 
progression. Amongst the mechanisms that can contribute to deregulation of these factors 
is the process of gene amplification that results in the overexpression of the amplified 
gene. Tbx2 is one such gene within the 17q23 amplicon (Barlund et al., 2000; Sinclair et 
al., 2002; Wu et al., 2001a). In prostate cancer, it has been reported that this region is 
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frequently amplified in 46% of late stage hormone refractory adenocarcinomas and in 
31% of metastases (Andersen et al., 2002). In a study of breast cancer cell lines using 
Southern blot and fluorescence in situ hybridization (FISH), Tbx2 was shown to be 
amplified three of six cell lines and the MCF7 cell line had 50 copies of the gene 
(Barlund et al., 2000; Sinclair et al., 2002; Wu et al., 2001a). Using microarray 
techniques, similar results were observed (Barlund et al., 2000). Tbx2 overexpression 
was confirmed by RT-PCR in each of the cell lines that had the amplification. In the 
study, Tbx2 was amplified in 8.6% of the cases in 372 primary breast tumors. In another 
study of breast tumors, Tbx2 was observed to be amplified 200-fold for one breast tumor 
(Rouillard et al., 2001). RT-PCR analysis was used to confirm over-expression of Tbx2. 
Further, Tbx2 was also found to be amplified in 19 of 27 BRCA1 and BRCA2 tumors as 
compared with 8 of 27 sporadic controls, thus showing that Tbx2 is preferentially over-
expressed in BRCA1 and BRCA2 associated tumors (Rouillard et al., 2001). In another 
study, Tbx2 was reported to be overexpressed in melanoma cell lines and shown to target 
histone deacetylase 1 to the p21Cip1 (CDKN1A) initiator. Expression of dominant 
negative Tbx2 resulted in up-regulation of p21cip1 and induced senescence in p21 null 
B16 melanoma cells. These results indicate that endogenous Tbx2 is critically required to 
enhance proliferation and suppress senescence in melanomas (Prince et al., 2004). 
 
Tbx2 and Sonic Hedgehog signaling:  
Sonic hedgehog (Shh) signaling has been reported to be upregulated in prostate 
tumors (Fan et al., 2004). Tbx2 and Sonic hedgehog regulate each other in a feedback and 
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feed forward mechanism. It has been shown that Tbx2 can activate the expression of Shh 
during the development of chick limb. Conversely, Shh signaling also regulates Tbx2 
(Rowley et al., 2004). Shh activates Tbx2 in the posterior mesenchyme in chick limb 
development (Suzuki et al., 2004; Tumpel et al., 2002). In another study looking at the 
role of Shh in mouse lung development, Tbx2 was found to be significantly repressed in 
Shh (-/-) mouse (Li et al., 2004). This tight feedback and feed forward mechanism of 
regulation between Tbx2 and Shh is essential for digit identity and proper lung 
development.  
 
BMP signaling, prostate cancer and Tbx2:  
Several reports have shown that BMPs can promote the development and 
progression of osteoblastic lesions in prostate cancer (Autzen et al., 1998; Bobinac et al., 
2005; Feeley et al., 2005; Thomas and Hamdy, 2000) Expression of BMP receptors 
correlate with the tumor grade in prostate cancers (Kim et al., 2000). In a study, BMP2 
stimulated cellular migration and invasion of prostate cancer cells in a dose dependent 
fashion (Feeley et al., 2005). Data from several experimental systems show that BMP 
(bone morphogenic protein) 2/4 signaling can activate Tbx2 expression. Conditional 
inactivation of BMP2 in mouse myocardium caused loss of Tbx2 expression (Ma et al., 
2005). Misexpression of Tbx2 in chick digit development caused misexpression of 
BMP2. Further, Tbx2 rescued noggin inhibited BMP signaling (Suzuki et al., 2004). 
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These data suggest a tight feed forward and feedback control of expression between Tbx2 
and BMP signaling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Tbx2 and its signaling pathways. Tbx2 represses p21 and p19arf / p14 arf at 
the transcriptional level. Also, Tbx2 has a feedforward - feedbackward regulation with 
Shh and BMP2. 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Generation of hepsin/myc mice: 
Mice were housed in the animal care facility at Vanderbilt University Medical 
Center in accordance with the National Institutes of Health (NIH) and institutional 
guidelines for laboratory animals. The PB-Hi-myc and PB-hepsin mouse models have 
been described elsewhere (Ellwood-Yen et al., 2003; Klezovitch et al., 2004). These 
models were generated by utilizing the probasin promoter (ARR2PB) to target the myc 
and hepsin genes, respectively, to the mouse prostate. The ARR2PB sequence consists of 
the original probasin sequence PB (-286/ +28) combined with an additional androgen 
response region (Zhang et al., 2000)(Zhang et al., 2000)(Zhang et al., 2000)(Zhang et al., 
2000)(Zhang et al., 2000)(Zhang et al., 2000)(Zhang et al., 2000). PB-hepsin and PB-Hi-
myc mice were maintained in CF7BL/6J and FVB backgrounds respectively. All the 
mice were F1 offspring so the PB-Hi-myc mice were age matched and genetically 
matched to the hepsin/myc mice, therefore the Pb-Hi-myc and hepsin/myc bigenic mice 
were 50% C57BL/6J and 50% FVB. Mice were analyzed starting at 3 months of age.  
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Tail Digestion and DNA isolation: 
A piece of mouse tail approx 2 cm was cut with the help of a sterile scissors and 
put in a tube on dry ice. 100 ml of the digestion buffer was made with 5 ml of 1M Tris-
Hcl Ph 8.0, 20ml of 0.5 M EDTA, 10 ml of 10% SDS, 2 ml of 5.0 M NaCl & 63 ml of 
DNA RNAse free water. The tube was incubated at 55 deg C with vigorous shaking 
overnight. The supernatant (500µl) was transferred at room temperature to 1 ml of 100% 
ethanol. The tube was then gently inverted so that the DNA strands would precipitate. 
With the help of a glass micro-capillary tube (Kimax-51 34505), the DNA strands were 
hooked out and transferred to a tube containing 1 ml of DNA RNA ase free water. The 
tube was then vortexed vigorously placed at 4 deg C so that the DNA would dissolve in 
the water.  
 
Whole dissection of the mice: 
Mice were sacrificed by cervical dislocation method following the inhalation of 
an anesthetic agent in accordance with the policy of the Vanderbilt University Animal 
Care Committee. The organs removed were as follows: prostate, seminal vesicle, testes, 
vas deferens, bladder, periurethral glands, bulbourethral glands, para-aortic lymph nodes, 
liver, spleen, kidney, and lung. Part of the tissue was fixed in 10% formalin for histology 
examination and the rest was frozen on dry ice and stored at -80
o 
C for RNA and protein 
extraction. As every prostate lobe exists as a pair, one of the pair was frozen while the 
other was fixed. 
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First, the genitourinary organs were removed. The mouse was anesthetized with 
isoflurane and sacrificed following cervical dislocation method. The abdominal area was 
sprayed with 95% ethanol and incisions were made longitudinally and horizontally to 
expose the abdominal cavity. The bladder was pulled with the aid of forceps and the 
prostate, seminal vesicles and urethra were identified. The urethra was cut below the 
prostate while the bladder was held with the foreceps. The bladder along with the 
attached genitourinary system was removed and was separated into the different lobes of 
the prostate (anterior, dorsal, ventral, lateral), seminal vesicle, bladder and urethra. 
Anatomically, all the prostate lobes are directly attached to the urethra. The anterior lobes 
run along the seminal vesicles, the ventral lobes rest on top of the bladder surrounded by 
the urethra while the dorsal lobes surround the urethra.  
Next, the remaining organs of the abdomen were removed. The para-aortic lymph 
nodes that are located on both sides of the abdominal aorta were removed. The testis and 
epididymi were removed and separated. The bulbourethral glands that are located on both 
sides of the urethra were removed. The kidneys, liver and spleen were removed.  
Finally, the organs of the chest cavity were removed. The chest area was sprayed 
with 95% ethanol and ribs and the chest cavity was exposed by cutting the ribs and 
sternum. The heart along with the entire lung was pulled out and the lung was separated 
from the heart. The neck was sprayed with ethanol and cut with longitudinal and 
horizontal incisions. The neck lymph nodes and the submandibular gland were removed. 
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Microtomy: 
Even though the rate of formalin fixation of tissue is 1 mm/hr, the tissue was fixed 
for 1 day for optimum histology. Following formalin fixation, the tissue was stored in 
50% ethanol at 4
o
 C until processing was performed. For fixing bone, decalcification was 
performed following formalin fixation by soaking in 5% formic acid at 4 
o
 C overnight, 
rinsed in tap water for 30 min, and then placed in 50% ethanol prior to processing. The 
paraffin embedded tissue block was placed on ice for atleast 30 minutes prior to 
microtomy. The Millipore waterbath was set at 42
o
 C and the microtome was adjusted to 
cut 5 µm thick sections. If the blades were new, the blades were run through Styrofoam 
three times prior to use to remove the Teflon coating which could cause a smear on the 
section. The blade was then placed deep in the microtome holder, such that the blade 
edge just stuck out of the holder, this was to minimize any vibration during cutting that 
could cause the tissue section to have “vertical blinds”. The angle of the blade was 
adjusted to 5 degrees. The piston holding the block was extended from the body of the 
microtome at the least possible distance to minimize vibration during cutting. The leading 
edge of the tissue chain was held with forceps and the blocks were cut quickly. With the 
help of a brush, the lagging end of the tissue chain was broken and the tissue chain was 
laid on the water bath. The brush was used to pull flat any creases that were created. 
Individual sections in the chain were separated by piercing holes at the border between 
sections with a skewer and the sections were pulled apart with a brush. The skewer was 
occasionally dipped in a 1:1 mixture of xylene and 100% ethanol to dissolve the borders. 
With the aid of a brush, the individual sections were moved across the water surface and 
placed on a partially immersed Superfrost Plus AAS coated slide (VWR Scientific) The 
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first two sections of any tissue chain were discarded since the thickness was not accurate 
due to expansion caused by the block warming up. The slides were allowed to dry by 
resting in an upright position after any extra moisture was removed by blotting away. The 
slides were then placed in an oven at 65
o
 C for 30 min so that the paraffin would melt 
away, thus ensuring that the tissue sections would not fall off during the experimental 
protocol. 
 
RNA Isolation: 
The protocol and reagents used were from the RNeasy Midi kit (Qiagen 75144). 
All the tools used were either sterilized or dipped in 3% HCl in 100% ethanol. A rotor-
stator homogenizer at setting 4 for 20 sec on ice was used to homogenize the tissue. In 
between samples, the homogenizor probe was washed with Millipore, DEPC water, and 
wiped clean with a Kimwipe tissue. RNA kit was then used to extract RNA from the 
homogenized tissue samples. The RNA samples were then diluted in 50mM NaOH or 
DEPC water to read the optical density at 260 nm (OD260) on a spectrophotometer.  The 
concentration of the RNA was calculated by the following formula: µg/µl = OD260 X 40 
(as RNA constant) x dilution factor x 1/1000 (unit conversion). For DNA, the constant 
used was 50.  
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Concentration of RNA or DNA by ethanol precipitation: 
For RNA, 1/10th the sample volume of 3M sodium acetate and 2.5X the sample 
volume of 100% ethanol was added to the sample. For DNA, 1/0
th
 the sample volume of 
3M sodium acetate and 2X volume of 100% ethanol was added to the sample. The 
samples were then placed at -80
o
 C for 1 hour and centrifuged at 15,000 rpm at 4
o
 C for 
30 minutes. The supernatant was discarded and the pellet was washed with 0.5 ml of cold   
(4
o
 C) 70% ethanol and centrifuged for 5 min at 15,000 rpm. After the ethanol was 
aspirated off, the pellet was resuspended in nuclease free water and the concentration was 
determined with the help of a spectrophotometer. 
 
Quantitative real-time reverse transcriptase polymerase chain reaction (q RT-
PCR): 
RNA was extracted from tissue samples fixed in RNA later using the RNeasy 
mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s protocol including 
treatment with DNase. RNA concentration was measured using a spectrophotometer and 
RNA quality was assessed by agarose gel electrophoresis. Hepsin copy  numbers were 
determined using a Lightcycler fluorescent temperature rapid-air cycler (Roche 
Molecular Biochemicals, Indianapolis, IN) with cDNA standard curves and the double-
stranded DNA-binding fluorescent probe SYBR green (Biorad, Hercules, CA, USA) The 
forward hepsin primer (5’ CTCTAGCTCCCTGCCTCTCA 3’) and reverse hepsin primer 
(3’ CGTTGCTTATGATGGGAACC 5’) generated a 170 bp amplimer. Melting curve 
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analysis that compared the melting curves from the samples, standards and negative 
controls confirmed the specificity of the amplimer in each reaction. Copy numbers of 
mRNA were calculated, using the Lightcycler software (version 3.5), from serially 
diluted (1:10) standard curves (10
9
-10
3
 copies). The standards that were serially diluted 
were simultaneously amplified along with the unknown samples to generate a linear 
standard curve using the fit points analysis method. Also, real-time RT-PCR was 
performed for 18S as a loading control using a cDNA template, the forward 18S primer 
(5' CAAGAACGAAAGTCGGAGGTTC), and the reverse 18S primer (5' 
GGACATCTAAGGGCATCACAG). 
One step RT-PCR was performed in a Lightcycler machine with 200 ng of RNA, 
1 mM of MgCl2, 1.25 µM each primer. Reverse transcription was performed at 55
 o
 C for 
15 min followed by denaturation at 95
 o
 C for 30 sec. Amplification was performed with 
45 cycles of 95
o
 C for 1 sec, 50
o
 C for 5 sec, 72
o
 C for 10 sec, and 82
o
 C at 5
o
 C / sec. for 
2 sec for single acquisition to quantiate the product. Melting was performed with 95
o
 C 
for 0 sec, 65
o
 C for 20 sec, and 95
o
 C at 0.1
 o
 C / sec for 0 sec for continuous acquisition 
to determine specificity. 
 
General Immunohistochemistry Protocol: 
Tissue sections that were 5 µm in thickness were deparaffinated and rehydrated 
by sequential washings in 100% xylene, 100% ethanol, 100% ethanol, 70% ethanol, and 
50% ethanol for 3 minutes each. The slide rack was then dipped in Millipore water. 10X 
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PBS buffer was made by mixing 160.0 g of NaCl, 4.0 g of KCl, 28.8 g of Na2HPO4, and 
4.8 g of KH2PO4 then make up the volume to 2 liters while adjusting the pH to 7.4. For 
optimization of signal, antigen retrieval was performed with 0.01 M citrate, 1 M urea, or 
proteinase K (DAKO S3020) digestion. The citrate solution was prepared by combining 
10.8 ml of 0.1 M anhydrous citric acid (Fisher A940-500; 1.91 G/100 ml), 49.2 ml of 0.1 
M tri-sodium citrate acid (Sigma C-8542; 14.705 g/500 ml), and 540 ml of H2O. The urea 
solution was prepared by dissolving 36.0 g of urea (Fisher BP 169-212) in 600 ml of 
millipore water. To perform antigen retrieval with citrate or urea solution, the slide rack 
was placed in the solution, the solution was heated (5 min 30 sec) to bring to boiling by 
microwaving at full power, then the solution was microwaved at 30% power for 20 
minutes, and cooled at room temperature for 1 hr. For antigen retrieval with proteinase K, 
the sections were incubated with the solution for 15 min at room temperature. 
Following antigen retrieval the slides were washed thrice in 1X PBS. The tissue 
sections on the slides were encircled with the help of a PAP pen. The slides were treated 
with Peroxidase Blocking Reagent (DAKO S2001) to block endogenous peroxidase 
activity. The slides were washed thrice in 1X PBS. Next, the slides were blocked with 
blocking buffer for 30 min at room temperature. The blocking buffer was either 1% DIG 
in Tris-NaCl pH 7.5 or 10% normal serum in 1X PBS. The 1% DIG in Tris-NaCl was 
prepared by combining 50 ml of 1M Tris-HCl pH 7.5, 15 ml of 5 M NaCl, 435 ml of 
H2O, and 5 g of DIG blocking reagent (Roche 1096176) then stirring until dissolved 
(about 1 hr). Normal serum was of the same animal origin as that of the secondary 
antibody. After blocking, the excess buffer was blotted off but the slides were not 
washed. Negative control solution (100 µl) was added to one section and the primary 
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antibody solution (about 100 µl) was added on top of the adjacent tissue section of the 
same slide, carefully making sure that each solution remained within the boundary of the 
encircled PAP pen. The negative control solution was normal IgG of the same animal 
origin and at the same concentration as the primary antibody in PBS, a 1:5 mixture of 
primary antibody and blocking peptide in PBS, or PBS alone. The primary antibody and 
negative control solutions were made with either 1X PBS or 2% filtered bovine serum 
albumin in 1X PBS. The slides were the placed in a covered, humidified slide box with 
wet paper towels at the bottom at 4
o
 C overnight. 
After the incubation with the primary antibody, the slides were removed from the 
humid chamber and washed thrice with 1XPBS for 5 minutes each time. Secondary 
antibody solution (about 100 µl) was added to each tissue section and the slides were 
incubated in a covered humid box for 2 hrs at room temperature. The secondary antibody 
was made either with 1X PBS or 2% bovine albumin serum and 5% normal serum in 1X 
PBS. The secondary antibody was aspirated off and the slides were washed with 1X PBS 
three times, 5 min each. Next, the tertiary antibody conjugated to horseradish peroxidase 
was added to the sections and the slides were incubated at room temperature for 1 hr. The 
tertiary antibody was blotted off and the slides were washed three times in 1X PBS for 5 
min each time. Slides were then immersed in 50 mM Tris-Hcl at pH 7.4 for a few 
minutes. DAB solution (3,3’ diaminobenzidine tetrachloride) was prepared using the 
Liquid DAB Substrate-Chromogen System (DAKO K3466). DAB solution (100 µl) was 
added to each slide individually and the sections were observed under a microscope for 
color development. The reaction was stopped by blotting off the excess DAB solution 
and the slides were immediately placed in H20.  
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The slides were counterstained with hematoxylin for nuclear visualization. 
Hematoxylin was filtered prior to each use. The slides were dipped twice in hematoxylin, 
twice in tap water, and placed under running tap water for 1 minute. Then the slides were 
dipped ten times in ammonium water, twice in tap water, and washed under running tap 
water for 1 minute. The slides were dipped in 95% ethanol for 20 times. The slides were 
dehydrated by dipping them sequentially in 100% ethanol, 100% ethanol, xylene, and 
xylene for 3 minutes each. The slides were transferred to a third container of xylene 
before being cover slipped with cytoseal 60 (Richard-Allan Scientific 83104). Any 
bubbles were pushed away from the tissue section by gently pressing with a forceps. 
The following primary antibodies were used (with the indicated dilutions in PBS): 
AR N-20 Santa Cruz Biotechnology Inc., sc-816 (1:1000); Foxa1 C-20 sc-6553 (1:1000), 
Hepsin Cayman Chemical cat# 100022 (1 μg/ml) and Myc N terminal antibody 
Epitomics cat #1472-1 (Gurel et al., 2008)(Gurel et al., 2008)(Gurel et al., 2008)(Gurel et 
al., 2008)(Gurel et al., 2008)(Gurel et al., 2008)(Gurel et al., 2008) (dilution 1:1000). 
Staining was visualized using Vectastain ABC kit (Vector Laboratories Inc, Burlingame, 
CA, USA) and 3,3'-diaminobenzidine tetrahydrochloride (Dako). 
 
Western Blot: 
The lysis buffer for protein extraction was prepared by mixing 10 ml of RIPA 
buffer (PBS at pH 7.4, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS), 100 µl of 100 
mM PMSF, and one tablet of Complete Mini protease inhibitor cocktail (Roche 
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1836153). Lysis buffer (6 to 10 times of tissue volume) was added to the frozen tissue. 
The tissue in lysis buffer was subjected to sonication at setting 5 for 20 sec. This was 
repeated 3 times until the tissue was homogenized.  Between samples, the probe was 
washed with distilled water and 95% ethanol then wiped with a Kimwipe. The 
homogenized tissue was centrifuged for 10 min at 14,000 at 4
o
 C. The supernatant that 
was proteinaceous was transferred to a new tube. Protein estimation of the samples was 
performed using the Bio-Rad Protein Assay (Bio-Rad Laboratories 500-0006) and a BSA 
standard curve measured at OD595 was carried out. The protein extract was stored at         
-80
o
 C.  
Protein electrophoresis was done utilizing the XCell SureLock Mini-Cell 
(Invitrogen E10001), 7% Tris-Acetate gels (Invitrogen EA035A), AND Tris-Acetate 
SDS Running Buffer (Invitrogen LA0041). Protein lysates were mixed with LDS sample 
buffer (Invitrogen NP0007) and β-mercaptoethanol then heated for 10 minutes at 70o C. 
The gel was securely placed the cell and the wells were flushed with the buffer with a 
pipette. The samples were centrifuges briefly, loaded onto the gel along with a protein 
ladder, and electrophoresed for about 1 hour at 150 volts. 
The proteins were transferred using the Mini Trans-Blot cell (Bio-Rad) and PVDF 
filter paper sandwich (Invitrogen LC2005). The 10X transfer buffer was prepared by 
combining 19.3 g of Tris base and 90 g of glycine, then making up the volume to 1 liter 
with water. The protein was run such that it migrated towards the red (positive) wall. 
Four filter papers were immersed in 1X transfer buffer. Two filter papers were placed on 
the black side of the sandwich case. The Tris-Acetate gel was then placed on top of the 
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filter papers. The membrane was placed on top of the gel. The remaining two filter papers 
were placed on top of the membrane. A falcon tube was rolled on top of the sandwich to 
remove any bubbles. The sandwich was closed and inserted into the cell with the clear 
side facing the red wall. A stir bar was placed at the bottom of the cell. The cell was filled 
with the transfer buffer and run at 30 volts while stirring for overnight at 4
o
 C.  
The membrane was removed from the cell and gently washed in distilled water 
with the protein side facing up. The membrane was stained with Ponceau S solution 
(Sigma P7170) to visualize the bands inorder to ensure that proper transfer occurred 
without air bubbles. The membrane was rinsed with distilled water 3 times remove excess 
Ponceau S. Next, the membrane was blocked by incubating with blocking buffer 
containing 5% skimmed milk dissolved in TBS-T buffer (200 mM Tris, 1.37 M NaCl, 
0.1% Tween-20). 10X TBS was prepared by combining 24.2 g of Tris and 80.0 g of NaCl 
then making up the volume to 1 liter with water while adjusting the pH to 7.6. 1 ml of 
Tween-20 was mixed to 1 liter of 1X TBS to make the TBS-T buffer. The membrane was 
blocked at room temperature for 1 hour while shaking gently. 
The membrane was washed three times with 1X TBT-T for 15 min each. For 
Laminin-332 detection, the membrane was incubated with primary polyclonal antibody to 
C-terminus of Ln-332 β3 chain (1:500 sc-20775; H-300; Santa Cruz Biotechnology, Inc). 
The membrane was washed three times with 1X TBS-T for 15 min each. Next, the 
membrane was incubated with horseradish peroxidase linked anti-rabbit Ig (Amersham 
NA9340) at 1:2000 dilution in blocing buffer for 2 hr at room temperature. The 
membrane was washed thrice with 1X TBS-T for 10 min each. 
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Protein bands were visualized using the ECL plus (Amersham RPN2132) and 
BioMax MR Film (Kodak 870-1302). Development of the film was performed in the dark 
room with red safety lighting. The ECL Plus reagents were mixed in a falcon tube. The 
membrane was dipped for one minute in the ECL Plus mixture and then blotted on paper 
to remove excess reagent. The coated membrane was wrapped in a plastic wrap, placed in 
a cassette and taped down. A piece of BioMax film was placed on top of the membrane, 
then the cassette was closed for the desired exposure time. The film was then run through 
the developer to produce the bands. The bands in the protein ladder were marked and 
used to determine the size of bands in the lanes.  
For β-actin visualization, the Laminin-332 Western membrane was stripped by 
incubation with the stripping solution (2% SDS, 62.5 mM Tris-HCl (pH 7.4), 100 mM β-
mercaptoethanol) for 30 minutes at 55
o
 C. The membrane was then blocked and probed 
with monoclonal anti-β-actin antibody (Sigma A5411) at 1:10,000 in blocking buffer 
followed by horseradish peroxidase linked anti-mouse Ig (Amersham NA931V) at 1:2000 
dilution in blocking buffer. Bands were visualized with ECL plus and Biomax MR Film. 
 
In situ hybridization: 
Freshly dissected prostates were rinsed twice in PBS and fixed in 4% paraformaldehyde – 
PBS fixative for 15 minutes to overnight depending on the size of the tissue mass with 
gentle rocking (in glass scintillation vials). Fixed tissue was then placed in cassettes and 
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dehydrated by washing at 4
o
 C with cold PBS followed washing with 50% ethanol, 70% 
ethanol, 90% ethanol and 100% ethanol for 30 minutes each.  
Fixation of the tissue was followed by embedding in paraplast. The tissue 
cassettes were then washed for 30 minutes each, in ethanol, mixture of ethanol and 
xylene, xylene, mixture of xylene and wax, and finally three times in wax. At the end of 
the third wax wash, tissues were oriented in the mold with a warmed foreceps and 
embedded blocks were stored at 4
o
 C before sectioning. The blocks were sectioned on 
slides previously washed in DEPC water and dried. The tissue sections were cut and 
placed on DEPC water before placing them on the slides. The slides were stored at 4
o
 C. 
The probe was prepared by adding 10 µl of DEPC H2O, 3 µl of 100 mM DTT, 3 
µL of 10x transcription buffer, 1 µl of 10mM rATP, 1 µl of 10mM rCTP, 1 µl of 10 mM 
rGTP, 1 µl of template DNA, 1 µl of RNase inhibitor, 10 µl of 
35
 – thio UTP  and 1 µl of 
enzyme (T7/T3/SP6). The probe was then incubated for 3 hours at 30
o
 C. The DNA 
template was digested by adding 1 µl DNase I and incubated at 37
 o
 C for 15-30 minutes, 
and the DNase was topped by adding 3 µl of 200 mM EDTA. The reaction volume was 
made up to 50 µl with DEPC-H2O and purified using Kodak NuClean R50 Disposable 
Spun Column. 10 µl of 10 mg/ml yeast tRNA was added and the reaction volume was 
made upto 100 µl by adding DEPC – H2O. 50 µl of 4M NH4-OAc and 200 µl of Et-OH 
was added, left at room temperature for 10 minutes and centrifuged at 15,000 rpm for 15 
minutes. The pellet was rinsed in 500 µl of 70% EtOH and resuspended in 100µl 10mM 
DTT and 1µl of RNase inhibitor was added. 2 µl of probe solution was taken and specific 
activity was counted by a scintillation counter. The probe was diluted with 10 mM DTT 
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so that the final activity was 1x10
6
 cpm/µl and the probe stock solution was stored at       
-70
 o
 C until use. 
The sections were pretreated for hybridization in the following manner: 
The tissue on the slides was prepared for hybridization by the removal of wax, 
leaving the sections intact on the slide. This was followed by a deproteinization step to 
make the tissue more porous to the probe. 
The slides were placed in a glass rack and transferred from one solution to the 
other in glass staining jars, tapping occasionally at each step.  The sections were dewaxed 
through a series of washes at room temperature: 
Xylenes      3 times, 5 minutes each 
100% ethanol      3 times, 2 minutes each 
95% ethanol      1 time, 2 minutes each 
70% ethanol      1 time, 2 minutes each 
50% ethanol      1 time, 2 minutes each 
H2O       2 times, 2 minutes each 
The sections were then acid treated to denature RNA at room temperature by the 
following way: 
0.2 M HCl      15 minutes 
H2O       rinse 
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PBS       3 times, 1 minute each 
The sections were then treated with proteinase K to permeabilize the cells as follows: 
(20 µg/ml proteinase K,    6-8 minutes 
50 Mm Tris pH 7.5, 5 mM EDTA) 
H2O       1 time, 5 minutes 
The sections were then post fixed at room temperature with 4% paraformaldehyde 
PBS for 15 minutes followed by 2 washes in PBS for 2 minutes and finally rinsed with 
water once for 2 minutes. The slides were then acetylated twice with a mixture of 0.1 M 
triethanolamine and acetic anhydride.  The sections were washed twice in H2O and air 
dried for 30 minutes before the hybridization step. 
For hybridization, a humidified box at 50
o
 C by using 50% formamide to soak 
tissue paper and kept tightly closed for 30-60 minutes. The hybridization mixture was 
prepared by adding 7 µl of DEPC- H2O, 50 µl of formamide, 10 µl of 10x salts, 2µl of 
tRNA, 1 µl of 1M DTT, 5µl of probe and 25 µl of dextran sulfate. This made the final 
probe concentration 5x10
4
 cpm/µl. Both sense and anti-sense probes were made.  The 
hybridization mixture was heated at 95
o
 C for 10 minutes and then spun down evaporated 
solution and incubated on ice for 2 minutes. 80 µl of probe mixture was put on the glass 
slide, and spread well over the sections with a tip. The section was carefully covered with 
a coverslip avoiding making air bubbles. The slides were incubated in the prepared 
humidified chamber at 50
o
 C overnight. 
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On Day 2, the coverslips were removed by immersing the slides one by one in 5x 
SSC solution at in a 60
o
 C water bath. The slides were washed in FSM in a 60 degree C 
waterbath for 30 minutes and washed twice in STE at 37
o
 C for 10 minutes. The slides 
were then incubated in STE containing 20 µg/ml RNase A at 37
o
 C for 30 minutes and 
then the slides were incubated in STE containing 20 mM β-Me at 37o C for 10 minutes. 
The slides were washed in FSM at 60
o
 C for 30 minutes. Next, the slides were washed in 
2x SSC at 37
o
 C and then in 0.1x SSC at room temperature for 5 minutes. Finally the 
slides were washed twice in distilled H2O and air dried for 3 hours. The slides were 
exposed to the x-ray film over night and developed the following day. 
 
Castration and administration of DHT: 
Mice were castrated and two weeks later were administered with DHT. The 
prostates lobes AP, DP, VP and LP were harvested from the uncastrated control and the 
castrated mice at various time points. The tissues were fixed overnight in RNA later and 
subsequently RNA was isolated. 
 
Tissue recombination and kidney capsule grafting: 
Pregnant rats were obtained and rat UGM was prepared from 18-day embryonic 
fetuses (plug date denoted as day 0). Urogenital sinuses were dissected from fetuses and 
separated into epithelial and mesenchymal components by tryptic digestion, as described 
previously.
 
UGM was then additionally reduced to single cells by a 90-min digestion at 
54 
 
37° C with 187 U/ml collagenase (Life Technologies Inc., Grand Island, NY, USA). 
After digestion the mesenchymal cells were washed extensively with RPMI 1640 tissue 
culture medium. Viable cells were then counted using a hemacytometer, with viability 
determined by Trypan blue exclusion. 
PC3-EV or PC3-Tbx2 DN cells were released from tissue culture plastic with 
trypsin, washed in growth medium containing 20% FBS, and viable cells were counted 
using Trypan blue exclusion and a hemacytometer. Cell recombinants were prepared by 
mixing 100,000 epithelial (PC3-EV or PC3-Tbx2 DN) cells with 300,000 mesenchymal 
cells in suspension. Cells were pelleted and resuspended in 50 µl of neutralized type 1 rat 
tail collagen prepared. 100,000 PC3-EV or PC3-Tbx2 DN epithelial cells without rUGM 
were also pelleted and resuspended in 50 µl collagen. The recombinants were allowed to 
set at 37° C for 15 min and were then covered with growth medium (RPMI 1640+5% 
FBS), and cultured overnight. Recombinants were then grafted beneath the renal capsule 
of adult male outbred athymic mice. All of the animals were housed in Vanderbilt 
University laboratory animal resource center with food and drinking water under 
controlled conditions (12 h light, 12 h dark, and 20 2°C).  
Hosts were killed at 4 weeks by anesthetic overdose followed by cervical 
dislocation. Kidneys were excised, and grafts were dissected free of the host kidney and 
then processed for histology and immunohistochemistry. The castrated mice were killed 
at 2 days or 2 weeks after castration. At 2 h prior to death, 5-bromo-2'-deoxyuridine 
(BrdU) (10 mg/kg body wt) was injected i.p. for in vivo labeling of proliferating cells. 
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Micro–computed tomography, X-ray, and histomorphometric analyses:  
For gross analysis of trabecular bone volume (BV),
 
formalin-fixed tibias were 
scanned at an isotropic voxel size
 
of 12 µm using a microCT40 (SCANCO Medical). The 
tissue
 
volume (TV) was derived from generating a contour around the
 
metaphyseal 
trabecular bone that excluded the cortices. The
 
area of measurement began at least 0.2 
mm below the growth plate
 
and was extended by 0.12 mm. BV included all bone tissue 
that
 
had a material density of >438.7 mgHA/cm
3
. These analyses
 
allowed for the 
calculation of the BV/TV ratio. The same threshold
 
setting for bone tissue was used for 
all samples. Radiographic
 
images (Faxitron X-ray Corp.) were obtained using an energy
 
of 35 kV and an exposure time of 8 s. The tumor volume (TuV)
 
was calculated as a 
function of the total TV of the tibial medullary
 
canal using Metamorph software 
(Molecular Devices). For histomorphometry,
 
three nonserial sections of tumor-bearing 
limbs were H&E
 
stained to assess the BV/TV ratio or with TRAcP to assess osteoclast
 
number per millimeter of bone at the tumor-bone interface using
 
Metamorph.
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CHAPTER III 
 
HEPSIN COPERATES WITH MYC IN THE PROGRESSION OF 
ADENOCARCINOMA IN A PROSTATE CANCER MOUSE MODEL 
 
Introduction: 
Following the development of prostatic intraepithelial neoplasia (PIN), the natural 
course of progression in human prostate cancer typically involves the development of 
adenocarcinoma with local invasion, and the final development of distal metastases.  
Transgenic mouse models provide an excellent opportunity to identify genes that 
contribute to the development of prostate adenocarcinoma, and to elucidate the molecular 
basis of prostate cancer progression in vivo. However, several transgenic mouse models 
develop androgen independent neuroendocrine cancer, and neuroendocrine 
pathophysiology does not reflect the predominant androgen dependent adenocarcinoma 
phenotype observed in human prostate cancer (Klezovitch et al., 2004; Masumori et al., 
2001; Perez-Stable et al., 1997). Thus, there is a need to develop and characterize novel 
transgenic models that better mimic prostate adenocarcinoma in humans.  
Proteolytic activity associated with both secreted and cell surface proteases are 
thought to play a critical role in progression of cancer to an advanced stage (Noel et al., 
1997; Woodward et al., 2007). Cell surface proteases have been hypothesized to play a 
role in the cleavage of extracellular matrix proteins that are components of the basement 
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membrane, thus allowing tumor cells to invade and metastasize (Birkedal-Hansen, 1995). 
Several studies have shown that hepsin, a type II  transmembrane serine protease (TTSP), 
is upregulated at both the mRNA and protein levels in more than 90% of human prostate 
cancers. For example, one study reported that hepsin is up-regulated by 34 fold in 
Gleason grades 4 and 5. (Landers et al., 2005; Stephan et al., 2004). Hepsin levels have 
been correlated positively with disease aggressiveness with highest hepsin expression 
levels present in tumors of Gleason grade 4/5 (Xuan et al., 2006). This suggests a role for 
hepsin in aggressive prostate cancers. A transgenic mouse model over-expressing hepsin 
in the prostate was created by using the prostate-specific probasin promoter (Klezovitch 
et al., 2004). Prostates in these mice showed normal cell proliferation and differentiation 
but the basement membrane showed disorganization (Klezovitch et al., 2004). Further, 
these hepsin transgenic mice when crossed with the LPB-Tag 12T-7f model showed 
significant tumor progression and metastases to the bone making it the only mouse model 
to develop bone metastases (Klezovitch et al., 2004). This study indicated that hepsin 
plays a key role in the progression of prostate cancer to a metastatic phenotype, 
consistent with the high levels of hepsin found in patients with advanced prostate cancer. 
However, these bigenic mice developed adenocarcinoma and neuroendocrine tumors at 
the primary site but the metastatic lesions are NE cancer, a rare type of human prostate 
cancer. 
To determine the role of hepsin in the progression of adenocarcinoma of the 
prostate, we crossed the PB-hepsin mice with PB-Hi-myc mice, the probasin directed 
myc mouse model of prostate adenocarcinoma. The PB-Hi-myc model (hereafter referred 
as myc mice)  expresses high levels of myc and develops adenocarcinoma by 6 months of 
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age (Ellwood-Yen et al., 2003). Herein we provide evidence that over-expression of 
hepsin in the myc tumors decreases the time required for development of adenocarcinoma 
from 6 months to 4.5 months. Further, with aging, the PB-hepsin/PB-Hi myc mice 
(hereafter referred to as hepsin/myc mice) developed a pathologically higher grade of 
tumor as compared to the tumors of the age-matched myc transgenic mice. In short, our 
data confirms that hepsin co-operates with myc in the progression of adenocarcinoma in a 
mouse model of prostate cancer and underscores the relevance of hepsin during prostate 
cancer progression indicating that enzymatic inhibition of hepsin activity may have 
therapeutic benefit. 
 
Characterization of hepsin/myc bigenic mice:  
Since both myc and hepsin genes are over-expressed in human prostate tumors 
(Chen et al., 2003; Dhanasekaran et al., 2001; Ernst et al., 2002; Halvorsen et al., 2005; 
Jenkins et al., 1997; Luo et al., 2001; Magee et al., 2001; Nesbit et al., 1999; Qian et al., 
1997; Sato et al., 1999; Singh et al., 2002), it was essential that we specifically drove 
expression of these transgenes to the luminal epithelial cells of the prostate in a temporal 
manner.  Immunohistochemical analyses revealed the presence of myc expression in the 
epithelial cells of the hepsin/myc and myc mice (Fig. 4, Panels A through F). 
Immunohistochemical analyses revealed that hepsin expression was low in the myc 
transgenic mice and, as expected, was higher in the hepsin/myc mice at all ages (Fig. 4, 
Panels G through L). Notably, the myc transgenic mice spontaneously developed a low 
level of endogenous hepsin that increased as the myc tumors progressed, consistent with 
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the elevated levels of hepsin found in advanced human prostate cancer (Landers et al., 
2005; Stephan et al., 2004).  Our results indicate that forced hepsin and myc transgene 
expression was specifically targeted to the epithelial compartment of bigenic mice and 
that as the transgenic myc mouse ages, hepsin is spontaneously expressed. 
Histological examination of prostates from the myc and hepsin/myc mice showed 
progressive tumor development with age (Figs. 5 and 6; Table 2).  The prostates were 
characterized by a pathologist in a blinded manner as either containing no histologic 
abnormality, low grade prostatic intraepithelial neoplasia (LGPIN), high grade prostatic 
intraepithelial neoplasia (HGPIN) or adenocarcinoma with various grades (Figs. 5 and 6; 
Table 2). A detailed mouse-by-mouse description of the histopathological findings has 
been provided in Table 2. LGPIN and HGPIN were described by crowding of epithelial 
cells within a gland but still bound by the basement membrane combined with cytologic 
abnormalities such as nuclear enlargement. HGPIN (Fig 5, Panel B) differed from 
LGPIN (Fig 5, Panels A & D) based on pronouncement of these features including 
nuclear atypia, increased number of heterochromatic nuclei and higher mitotic rates.. 
Adenocarcinoma was characterized by invasive lesions that lacked glandular prostate 
differentiation and absence of a clear basement membrane contour (Fig 5, Panels C, E 
&F; Fig 6, Panels A through F; Table 2). This data indicates that hepsin/myc bigenic 
mice develop histo-pathological hallmarks associated with adenocarcinoma. 
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Figure 4: Immunohistochemical staining of myc and hepsin in the transgenic 
animals showing progression from 12 to 17 months. (Panels A & G) Myc staining and 
Hepsin staining respectively of 12 month old myc mice; (Panels D & J) Myc staining and 
Hepsin staining respectively of 12 month old hepsin/myc mice; (Panels B & H) Myc 
staining and Hepsin staining respectively of 15 month old myc mice; (Panels E & K) 
Myc staining and Hepsin staining respectively of 15 month old hepsin/myc mice; (Panels 
C & I) Myc staining and Hepsin staining respectively of 17 month old myc mice ; (Panels 
F & L) Myc staining and Hepsin staining respectively of 17 month old hepsin/myc mice   
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Figure 5: Histopathology (H&E) of transgenic animals showing progression from 3 
to 6 months. Panels A & D showing LGPIN in 3 month old myc and hepsin/myc mice 
respectively; Panel B showing HGPIN & Panel E showing adenocarcinoma in 4.5 month 
old myc and hepsin/myc mice respectively; Panel C & F showing adenocarcinoma  in 6 
month old myc and hepsin/myc mice respectively. 
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Fig. 6: Histopathology (H&E) of transgenic animals showing progression of 
adenocarcinoma from 12 to 17 months. (Panels A & D) H&E of 12 month old myc and 
hepsin/myc mice respectively; (Panels B & E) H&E of 15 month old myc and 
hepsin/myc mice respectively; (Panels C & F) H&E of 17 month old myc and hepsin/myc 
mice respectively.  
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Hepsin/myc bigenic mice display accelerated tumor progression:  
The PB-hepsin transgenic mice when crossed with the LPB-Tag mice has been 
shown to display significant progression from HGPIN to adenocarcinoma and NE 
cancers (Klezovitch et al., 2004). Further, these NE cancers metastasized to the liver, 
lungs, and bone (Klezovitch et al., 2004).  Our model tested if the overexpression of 
hepsin causes progression of adenocarcinoma in the myc model. Since adenocarcinoma 
develops first in the dorsolateral prostate of the myc mouse, the histology of these lobes 
was carefully examined in the hepsin/myc bigenic mice. We found that at 3 months, both 
myc and hepsin/myc mice displayed PIN lesions (Fig. 5, Panels A & D; Table 2). But 
notably, in contrast to the myc mice, the hepsin/myc mice displayed adenocarcinoma at 
4.5 months (5 out of 6 mice) since all the PIN lesions had advanced to adenocarcinoma  
(Fig 5, Panel E; Table 1; Table 2) whereas none of the myc mice displayed 
adenocarcinoma (0 out of 6 mice) but instead  developed HGPIN (Fig. 5, Panel B; Table 
1; Table2; p=0.015).  At 6 months, both hepsin/myc and myc mice displayed invasive 
adenocarcinoma (Fig. 5, Panels C & F; Table1). Since Foxa1 is an established marker to 
detect prostate luminal epithelial cells, invasion of the tumor cells into the surrounding 
stroma can be visualized by Foxa1 staining. (Fig. 7, Panels A through F; Fig. 8, Panels A 
through F). It has been previously shown that hepsin causes significant progression of 
prostate cancer in the LPB-Tag model including metastases to the bone (Klezovitch et al., 
2004). These tumors were shown to express neuroendocrine markers including 
synaptophysin (Klezovitch et al., 2004). In our model of the hepsin/myc mouse, 
neuroendocrine differentiation, as detected by synaptophysin staining was negative (Fig. 
10).  Further, to check the status of the androgen receptor in the tumors, we performed 
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immunohistochemistry with androgen receptor (Fig. 7, Panels G through L; Fig. 8, 
Panels G through L). Both myc and hepsin/myc tumors at all ages stained positive for the 
androgen receptor. This data indicates that when compared to myc transgenic mice, 
bigenic hepsin/myc mice develop adenocarcinoma at an accelerated rate and that both 
myc and hepsin/myc tumors are adenocarcinomas devoid of any neuroendocrine (NE) 
differentiation. 
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Figure 7: Immunohistochemical staining of Foxa1 and AR in the transgenic animals 
showing progression from 3 to 6 months. (Panels A & G) Foxa1 and AR staining 
respectively of 3 month old myc mice; (Panels D & J) Foxa1 and AR staining 
respectively of 3 month old hepsin/myc mice; (Panels B & H) Foxa1 and AR staining 
respectively of 4.5 month old myc mice; (Panels E & K) Foxa1 and AR staining 
respectively of 4.5 month old hepsin/myc mice; (Panels C & I) Foxa1 and AR staining 
respectively of 6 month old myc mice; (Panels F & L) Foxa1 and AR staining 
respectively of 6 month old hepsin/myc mice. 
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Figure 8: Immunohistochemical staining of Foxa1 and AR in the transgenic animals 
showing progression from 12 to 17 months. (Panels A & G) Foxa1 and AR staining 
respectively of 12 month old myc mice; (Panels D & J) Foxa1 and AR staining 
respectively of 12 month old hepsin/myc mice; (Panels B & H) Foxa1 and AR staining 
respectively of 15 month old myc mice; (Panels E & K) Foxa1 and AR staining 
respectively of 15 month old hepsin/myc mice; (Panels C & I) Foxa1 and AR staining 
respectively of 17 month old myc mice; (Panels F & L) Foxa1 and AR staining 
respectively of 17 month old hepsin/myc mice. 
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Prostate tumors from aged hepsin/myc mice exhibit a higher grade of 
adenocarcinoma compared with myc mice: 
In an effort to determine if increased hepsin expression in the tumors would lead 
to further progression, mice were aged up to 17 months.  Staining with the GFP antibody 
[since the mouse PB-hepsin construct is tagged with GFP (Klezovitch et al., 2004)] was 
used to detect potential metastasis in the lymph nodes, femur and jaw bones, kidney, 
lung, liver etc. No metastases were detected. Notably, hepsin/myc tumors (12-17 months) 
exhibited a higher grade adenocarcinoma as compared with the myc tumors (4 out of 6 
mice) (Fig. 6; Table 1; Table 2). (A detailed mouse-by-mouse description of the 
histopathological findings along with the grades of the respective tumors has been 
provided in Table 2.) The tumor size was not significantly different between hepsin/myc 
and myc mice.  As expected, hepsin levels were significantly higher (p<0.05) in the 
tumors of hepsin/myc mice compared with age matched myc tumors, as measured by 
quantitative real-time, qRT-PCR (Fig. 9) and immunohistochemistry (Fig. 4, Panels G 
through L). Notably, hepsin/myc tumors displayed less stroma as compared with the myc 
alone tumors. To determine if tumors in the myc mice reflected the pathobiology of 
human adenocarcinoma, we analyzed hepsin expression of myc tumors during 
progression from PIN to higher grade cancer. Notably, with aging, the prostates of the 
myc mice begin to spontaneously express hepsin. Further, hepsin expression in the myc 
tumors increased significantly (p<0.05) in the 12, 15 and 17 month time points compared 
to 6 month prostate tumor from myc mice (Fig. 9). This change in hepsin expression also 
was detected by immunohistochemistry (Fig. 4, Panels G through I). This data indicates 
that hepsin expression in the hepsin/myc tumors causes the tumors to progress to a higher 
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grade and that endogenous hepsin expression in the myc tumors increases with age 
progression. 
 
 
Figure 9: Quantitative real-time q RT-PCR of hepsin expression in hep/myc and 
myc mice: Hepsin expression in 6, 12, 15 and 17 month hep/myc and myc mice. (*) 
represents significant difference (p<0.05) in hepsin expression between myc and hep/myc 
mice. (+) represents significant difference (p<0.05) in hepsin expression between 6 
month old myc mice as compared with  12, 15 and 17 month old myc mice respectively.  
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Table 1: 
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Figure 10: Negative synaptophysin staining in myc and hep/myc transgenic mice. 
Myc (panel B) and hep/myc (panel C) tumors are negative for synaptophysin, a marker of 
neuroendocrine differentiation 
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Table 2: 
Mouse Strain / Age / 
Number 
Description of Pathology 
Myc / 3 mos / A8906 PIN lesions 
Hep Myc / 3 mos / A8905 PIN lesions 
Myc / 4.5 mos / A8914 High Grade PIN 
Hep Myc / 4.5 mos / A8913 Adenocarcinoma, nuclear enlargement, focal hyperchromatin, 
rare nucleoli, focal areas of glandular infiltration, single area 
of infiltrative glandular loss 
Grade 2+ 
Myc / 4.5 mos / A9171 PIN lesions 
Hep Myc / 4.5 mos / A9185 Adenocarcinoma, minute area of infiltrative glands with mild 
nuclear enlargement, rare nucleoli, stipled chromatin, loss of 
cell borders 
Grade 1+ 
Myc / 4.5 mos / A9166 PIN lesions 
Hepsin Myc / 4.5 mos / A9186 Adenocarcinoma, nuclear enlargement, hyperchromatia, 
infiltrative glands 
Grade 2+ 
Myc / 4.5 mos / B310 High Grade PIN 
Hepsin Myc / 4.5 mos / A9187 Adenocarcinoma, primarily gland forming with infiltrative 
focal areas of gland formation, nuclear enlargement, stipled 
chromatin, prominent nucleoli 
Grade 2+ 
Myc / 4.5 mos / A9163 PIN lesions 
Hepsin Myc / 4.5 mos / B307 PIN lesions 
Myc / 4.5 mos / B301 PIN lesions 
Hepsin Myc / 4.5 mos / B302 Adenocarcinoma, mild nuclear enlargement, single minute 
foci of infiltrative gland  
Grade 1+ 
Myc / 6 mos / A8912 Adenocarcinoma, infiltrative glands, nuclear enlargement, 
stipled chromatin 
Grade 2 
Hepsin Myc / 6 mos / A8921 Adenocarcinoma, areas of glandular infiltration, nuclear 
enlargement, stipled chromatin 
Grade 2 
Myc / 12 mos / A9935 Adenocarcinoma with gland formation and loss of gland 
formation, no definable single cells, nuclei hyperchromatic, 
vesiculated; prominent nucleoli, stipled chromatin and 
granulated cytoplasm 
Grade 2 
Hepsin Myc / 12 mos / A9952 Adenocarcinoma with very little gland formation, nuclear 
enlargement, stipled chromatin, prominent nucleoli, loss of 
cell borders with cells streaming and in sheets, rare 
rudimentary gland formation  
Grade 3+ 
Myc / 12 mos / A9946 Adenocarcinoma with gland formation and loss of gland 
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formation, nuclear enlargement, stipled chromatin, 
macronucleoli, focal loss of cell borders, cells are in cohesive 
bundles 
Grade 2 
Hepsin Myc / 12 mos / A9936  Adenocarcinoma, nuclear enlargement, stipled chromatin, 
prominent nucleoli, focal macronucleoli, primarily loss of 
glandular formation with focal glandular formation with focal 
single cells, reactive stroma 
Grade 2+ 
Myc / 12 mos / A8912 Adenocarcinoma with gland formation and loss of gland 
formation, nuclear enlargement, hyperchromatic, focal 
macronucleoli,  loss of cell borders, high apoptotic rate 
Grade 2 
Hepsin Myc / 12 mos / A9930 Adenocarcinoma with complex gland formation, nuclear 
enlargement, prominent nuclei with abundant macronucleoli, 
some loss of cell borders, scattered apoptosis 
Grade 2+ 
Myc / 15 mos / A9190 Adenocarcinoma with gland formation, mild nuclear 
enlargement, stipled chromatin, scattered prominent nucleoli 
Grade 1+ 
Hepsin Myc / 15 mos / A9180 Adenocarcinoma with tightly packed glands with focal loss of 
gland formation, sea of cells, stipled chromatin, no nuclear 
enlargement, rare prominent nucleoli, granular cytoplasm with 
loss of borders 
Grade 3+ 
Myc  / 17 mos / A9162 Adenocarcinoma with complex gland formation, focal loss of 
gland formation, nuclear enlargement, prominent 
macronucleoli, granular cytoplasm with loss of cell borders 
Grade 3+ 
Hep Myc / 17 mos / A9181 Adenocarcinoma, primarily gland forming with focal loss of 
gland formation, prominent nucleoli with focal macronucleoli, 
hyperchromatin, nuclear enlargement, stipled chromatin 
Grade 2+ 
Myc / 17 mos / A9174 Adenocarcinoma, stipled chromatin, prominent nucleoli with 
areas of macronucleoli, gland formation with areas of 
glandular loss, small areas of infiltrating individual cells, focal 
stromal response 
Grade 2+ 
Hepsin Myc / 17 mos / A9173 Adenocarcinoma, stipled chromatin, prominent nucleoli, 
scattered macronucleoli, glandular formation with some areas 
of glandular loss 
Grade 2+ 
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CHAPTER IV 
 
BLOCKING ENDOGENOUS TBX2 IN PC3 HUMAN PROSTATE CANCER 
CELLS DECREASES THE OSTEOLYTIC BURDEN WHEN GRAFTED IN THE 
BONE MICROENVIRONMENT 
 
Introduction: 
Bone metastasis is a leading cause of mortality and morbidity in human prostate 
cancer patients with up to 90% of advanced hormone refractory disease cases have 
clinical evidence of bone metastases. After homing in the bone, prostate cancer cells 
adapt themselves to the new environment of the bone, a process termed as 
“osteomimicry” by secreting growth factors that are abundant in the bone milieu 
(Koeneman et al., 1999).  This interaction between prostate cancer cells and the bone 
creates a vicious cycle of bone formation and bone destruction thereby destabilizing the 
inherently delicate homeostasis within the bone. In prostate cancer, this process leads to 
metastatic lesions that are predominantly osteoblastic. However within the background of 
bone formation, several groups have reported that bone resorption is an integral part of 
prostate cancer bone lesions. 
Tbx2 belongs to the T-box family of transcription repressors that play important 
roles in tissue development. Tbx2 is known to repress the senescence mechanism and 
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thereby promote immortalization by negatively regulating p21 and p19 arf genes 
(reference). Tbx2 has been reported to be upregulated in breast, pancreatic and melanoma 
cancer cell lines. The gene lies in the 17q23 amplicon that has been reported to be 
frequently amplified in 46% of late stage hormone refractory adenocarcinoma and 31% 
of metastases. Further, Tbx2 has been reported to regulate Shh and BMP2 genes in a 
feedback and feedforward mechanism and both the Shh pathway and BMP2 have been 
reported to be dysregulated in human prostate cancer. We have found in this study that 
Tbx2 is over-expressed in the more aggressive human prostate cancer cell lines as 
compared to the benign ones and this expression correlates with BMP2 expression in the 
same cell lines. Further, BMP2 induces Tbx2 expression in human prostate cancer cells 
in a time dependent manner. Further, using an intra-tibial model of tumor grafting, we 
have found that blocking endogenous Tbx2 in PC3 human prostate cancer cell line 
reduces tumor burden and the osteolytic activity when compared to the control cells. 
Since blocking BMP2 pathway has been postulated to be a clinical approach to reducing 
the osteogenic burden in human prostate cancer bone lesions, manipulating Tbx2 could 
be a potential approach for such a therapy in the future. 
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Tbx2 is over-expressed in aggressive prostate cancer cell lines that express high 
levels of BMP2: 
We examined Tbx2 expression by quantitative real time PCR in human prostate 
cancer cell lines (Fig 11a). Tbx2 is expressed in low levels in the less aggressive human 
prostate cancer cell lines RWPE1, LNCaP and C42-B whereas Tbx2 is over-expressed in 
the more aggressive PC3, DU145 and LAPC4 cell lines. RWPE1 and LNCaP are 
androgen dependent cell lines, while C42-B is a derivative of LNCaP cell line that is 
androgen independent. All three cell lines are relatively benign prostate cell lines while 
PC3, DU145 and LAPC4 are aggressive human prostate cancer cell lines that have been 
reported to form aggressive invasive tumor xenografts in mouse models. Interestingly, 
the human prostate cancer cell lines that we examined to have high levels of Tbx2 also 
express high levels of BMP2 (Fig 11b). We also looked at Tbx2 expression in mouse 
prostate by in-situ hybridization technique and Tbx2 expression appears to be epithelial 
in nature (Fig 12).  
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Figure 11a: Quantitative real-time PCR showing relative mRNA expression of Tbx2 
in prostate cancer cell lines. Tbx2 is expressed in low levels in the benign human 
prostate cancer cell lines RWPE1, LNCaP and C4-2B but is expressed in very high levels 
in the aggressive cell lines including PC3, DU145 and LAPC4.  
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Figure 11b: Quantitative real-time PCR showing relative mRNA expression of 
BMP2 in prostate cancer cell lines. BMP2 is expressed in low levels in the benign 
human prostate cancer cell lines RWPE1, LNCaP and C4-2B but is expressed in very 
high levels in the aggressive cell lines including PC3, DU145 and LAPC4.  
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Figure 12: In situ hybridization showing Tbx2 expression in 10 week dorsal lobe of 
normal mouse prostate. Tbx2 appears to be expressed in the epithelial cells of the 
mouse prostate. 
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Tbx2 expression is androgen regulated:  
We looked at the effect of androgens on Tbx2 expression by treating LNCaP cells 
with either androgen DHT or ethanol as control (Fig. 13). LNCaP cells have very low 
levels of endogenous Tbx2. Upon DHT administration, Tbx2 expression was induced 
after 2 hours and continued to be induced until 12 hours post DHT treatment. PSA 
expression was used as a positive control. The maximum induction was seen after 12 
hours of treatment. Following this in vitro study, we check Tbx2 expression in castrated 
mice that are administered with DHT. Seven week old mice were castrated for 2 weeks 
and administered with androgen (DHT) or ethanol for various time points. Consistent 
with the results observed in LNCaP cells, we saw a slight induction of Tbx2 as early as 
15 minutes after DHT treatment in the anterior (AP) and ventral (VP) prostate lobes of 
the mouse prostate suggesting that Tbx2 is directly regulated by the androgens. This 
induction is clearly seen 48 after DHT treatment (Fig 14). A transcription factor search of 
the human Tbx2 promoter has revealed a consensus glucocorticoid response element 
(GRE), a DNA sequence that has routinely been used to mimic an androgen response 
element (ARE).   
To test the possibility if the androgen receptor (AR) binds and regulates Tbx2 
expression, we utilized a 960 base pair Tbx2 promoter-luciferase construct, transfected in 
LNCaP cells and performed a luciferase assay. Since BMP2 and retinoic acid are also 
known to regulate Tbx2 expression, we included BMP2 and retinoic acid treatments in 
addition to androgens (DHT). Following serum starvation, we treated LNCaP cells with 
either DHT, BMP2, retinoic acid or in combinations (Fig. 15). Neither individual 
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treatments nor combinations of the three produced any appreciable luciferase activity.  In 
contrast, the positive control for the luciferase experiment, the ARR2PB luciferase 
construct gave a robust activity with the addition of DHT. It is possible that the GRE / 
ARE sequence in the 960 bp Tbx2 promoter is not the correct hormone response element 
or that it functions in a cooperative manner with additional AREs that are further 
upstream of the 960 bp promoter.  
 
 
 
Figure 13: RT-PCR analysis showing induction of Tbx2 in LNCaP cells after DHT 
treatment. Induction of Tbx2 mRNA after 2,4,8 and 12 hours of DHT treatment. 
Induction of PSA is used as control in the lower panel. 
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Figure 14: RT-PCR analysis showing induction of Tbx2 in the mouse prostate tissue 
after various times of DHT administration following 2 weeks of castration. Induction 
of Tbx2 mRNA in the anterior prostate (AP), ventral prostate (VP) and dorsal prostate 
(DP) after 15 minutes and 48 hours of DHT administration to male mice subsequent to 2-
week castration. Lower panels show GAPDH as control. 
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Figure 15: Luciferase assay showing that the 960 base pair Tbx2 promoter does not 
respond to DHT, RA, BMP2 or in combinations. 
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BMP2 induces Tbx2 and Wnt 3a expression: 
Since it is previously known that BMP2 induces Tbx2 expression in other 
developmental model systems, we wanted to test if BMP2 can stimulate Tbx2 expression 
in prostate cancer cells. Following serum starvation for 48 hours, we treated LAPC4 
cells, an androgen dependent human prostate cancer cell line with BMP2 at a 
concentration of 50 ng/ml. BMP2 induced Tbx2 expression robustly after 24 hours of 
treatment and remained induced in the 48 and 72 hour time points. (Fig. 16) Tbx2 is 
known to inhibit p16 arf expression and we observed inhibited p16 arf expression at 24 
and 48 hour time points. (Fig. 16) The increased p16 arf expression at the 72 hour time 
point is not clear at this time. Though Tbx2 is also known to inhibit p21 expression, we 
observed that p21 expression is also induced after 24 hours. (Fig. 16) Since BMP2 is 
known to signal through Wnts, we checked the expression of Wnt genes following BMP2 
addition to LAPC4 cells. Of all the canonical and non-canonical Wnts we examined by 
RT-PCR, we observed that Wnt 3a, a canonical Wnt, is induced after 24 hours following 
the addition of BMP2. (Fig. 16) The induction of Tbx2 and Wnt 3a following BMP2 
addition has interesting implications from the bone metastasis point of view. 
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Figure 16: RT-PCR analysis showing change in mRNA expression of Tbx2, p21, p16 
Arf and Wnt 3a in LAPC4 cells with BMP2 treatment. Tbx2 mRNA is induced after 
24 hours of BMP2 treatment in LAPC4 cells. p21 levels increase with BMP2 treatment 
while p16 levels decrease. Wnt 3a levels increase after 24 hours.  
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Characterization of prostate cancer cell lines stably infected with Tbx2 DN vector: 
We chose two androgen independent human prostate cancer cell lines DU145 and 
PC3 to block endogenous Tbx2 expression with the help of a Tbx2 dominant negative 
construct. We also chose the NeoTag-2 cells (a cell line generated from the LPB Tag 
12T-7 mouse model of prostate adenocarcinoma) to block Tbx2 expression. The NeoTag-
2 cells are androgen dependent. In addition, we used the LAPC4 cells to introduce the 
dominant negative construct. The NeoTag-2 cells when recombined with rat UGM (to 
induce prostate development) and placed in the kidney form foci of adenocarcinoma. 
Therefore it is interesting to see what effect knocking down of Tbx2 has on the 
adenocarcinoma morphology formed by Neotag-2 cells recombined with UGM.  We 
characterized all the four prostate cancer cell lines stably infected with the Tbx2 
dominant negative construct for HA tag (the Tbx2 DN construct contains an HA tag), p21 
or p19 arf expression. As expected, all four cell lines having dominant negative vector 
showed the expression of HA Tag (Fig. 17). All the three human cell lines LAPC4, PC3 
and DU145 showed enhanced expression of p21 expression as expected (Fig. 17).  
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Figure 17: Western blot analysis showing characterization of human prostate cancer 
cells stably infected with Tbx2 DN vector as compared to control cells Presence of 
HA tag and increase in p21 levels in human prostate cancer cell lines stably infected with 
Tbx2DN vector as compared to the respective empty vector (EV) infected control cells. 
Lower panel shows the cartoon depicting the construction of the inducible Tbx2 
dominant negative vector.  
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Tbx2 DN vector decreases proliferation of prostate cancer cells in vitro: 
Cell proliferation assays shoed that prostate cancer cells stably infected with the 
Tbx2 DN vector showed decreased proliferation in vitro as compared with the respective 
cells infected with the empty vector (EV). This was seen in three human prostate cancer 
cell lines PC3, DU145, LAPC4 (Fig 18). 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: In vitro Cell proliferation assay showing reduced proliferation in human 
prostate cancer cells stably infected with Tbx2 DN vector. 
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Kidney capsule grafts of PC3-Tbx2 DN vector show no difference in size of grafts 
compared with PC3-EV grafts: 
In order to find the in vivo effect of blocking endogenous Tbx2, we utilized the 
technique of tissue recombination and grafted PC3-Tbx2 DN and PC3-EV after 
recombining the cells with urogenital mesenchyme (UGM). Tissue recombination is a 
technique that makes use of epithelial-stromal interactions and this technique can be 
utilized to simulate and examine disease progression in the prostate by genetically 
modifying either the epithelial or the stromal cells. Contrary to expectations, we did not 
observe a statistical difference in the size of the grafts in PC3-Tbx2 DN and PC3-EV 
cells. Morphologically, PC3-EV grafts looked loose while PC3-Tbx2 DN grafts looked 
more compact (Fig. 19). 
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Figure 19: Tissue recombination scheme and H&E staining of tissue recombination 
grafts of PC-EV and PC3-Tbx2 DN cells. 
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Tbx2 DN cells grafted in the bone produce grafts that are less osteolytic as 
compared with PC3-EV grafts: 
In order to test the role played by Tbx2 in the growth of prostate cancer cells in 
bone microenvironment, we inoculated (2x10
5
 cells in 10ul PBS) of either PC3-EV or 
PC3-Tbx2 DN cells utlizing the technique of intra-tibial inoculation in the tibia of nude 
mice. As a control, the contra-lateral tibia of the mouse was injected with 10 ul PBS. 
Intra-tibial inoculation (Fig. 20, Upper Panel) is a technique which allows us to study the 
growth and effect of tumor cells on the bone microenvironment. In this technique, tumor 
cells are injected into the tibia of mice, the injected cells form lesions in the bone and the 
nature of these lesions, whether osteoblastic (bone forming) or osteolytic (bone depleting) 
is monitored and analyzed by weekly X-rays and the size of lesions is quantitated by 
using micro CT analyses. 
PC3 cells when injected in the tibia are known to be osteolytic in nature. As 
analyzed by x-ray analysis after 4 weeks of inoculation, we found that PC3-Tbx2 DN 
cells were reduced in their ability to elicit an osteolytic response in the bone as compared 
to PC3-EV cells (Fig. 20, Lower Panel). Also, the size of PC3-Tbx2 DN lesions was 
smaller as compared to PC3-EV cell lesions as seen on X-ray as well as by H&E analyses 
(Fig. 21) of bone tibial sections performed after fixation of harvested tibiae. Micro CT 
analysis revealed that the bone lesions formed by PC3-Tbx2 DN cells were more 
osteolytic as compared with bone grafts of PC3-EV cells (Fig 22, Upper Panel). The bone 
loss was quantitated and plotted in a graph (Fig. 22, Lower Panel). 
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Figure 20: Cartoon of intra-tibial inoculation model and x-ray pictures of mouse 
tibia injected with PC3-EV and PC3-Tbx2DN cells respectively. Upper panel shows 
cartoon depicting the intra-tibial inoculation model. Lower panel shows x-ray pictures of 
mouse tibia injected with PC3-EV and PC3-Tbx2DN cells respectively. 
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Figure 21: H&E analysis showing tumor lesions in PC3-EV and PC3-Tbx2DN 
injected tibiae respectively. Bone lesions of PC3 human prostate cancer cells infected 
with Tbx2 DN vector show reduced size of lesion compared to empty vector (EV) 
infected PC3 cells. 
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Figure 22: Micro CT analysis showing osteolysis in PC3-EV and PC3-Tbx2 DN 
injected cells in the tibiae. Lower panel shows the quantitation of bone loss. 
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PC3-Tbx2 DN cells show reduced levels of Wnt 3a, Gli2 and PTHrP as compared 
with PC3-EV cells: 
Since we found that BMP2 treatment induces Wnt 3a in LAPC4 prostate cancer 
cells, we looked at Wnt 3a in Pc3-Tbx2 DN cells. Interestingly, PC3-Tbx2 DN cells in 
vitro showed a reduction in Wnt 3a levels as compared to PC3-EV cells by real-time 
quantitative PCR analysis (Fig. 23).  We also looked at Gli2 and PTHrP since Wnt 3a has 
been reported to regulate Gli2 and Gli2 has been reported to regulate PTHrP. 
Interestingly, we found that both Gli2 and PTHrP were reduced in PC3-Tbx2 DN cells as 
compared with PC-EV cells by real-time quantitative PCR analysis (Fig. 23). 
 
 
 
Figure 23: Quantitative RT-PCR analysis showing change in expression of Wnt3a, 
Gli2 and PTHrP in PC3-EV and PC3-Tbx2DN cells. 
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PC3-Tbx2 DN cells show a reduction in nuclear phospho SMAD 1,5,8 levels in vitro:  
Since BMP2 is known to signal through downstream SMAD 1,5,8, we looked at 
SMAD 1,5,8 levels in PC3-Tbx2 DN cells. In vitro, PC3-Tbx2 DN cells showed reduced 
nuclear levels of SMAD 1,5,8 as compared with PC3-EV cells (Fig 24).  
 
 
 
 
 
 
 
 
Figure 24: Western blot analysis of cytoplasmic and nuclear fractions showing 
change in SMAD 1,5,8 levels in PC3-EV and PC3-Tbx2 DN cells respectively. PC3 
human prostate cells stably infected with Tbx2 DN vector show reduced levels of nuclear 
phosphor SMAD 1,5,8 as compared to empty vector (EV) infected PC3 cells. 
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CHAPTER IV 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
Metastasis to the bone occurs in up to 70% of patients with advanced prostate or 
breast cancer and these two cancer types account for a staggering 80% of the total cases 
with metastatic bone involvement (Coleman, 1997; Coleman, 2001; Roodman, 2004). 
Most of the patients who suffer from prostate cancer do not die due to the tumor at the 
primary site but rather due to complications when the tumor has spread to the bone. It is 
estimated that each year, about 350,000 people die of bone metastasis in the United 
States. The causative tumor becomes incurable once the bone has been invaded and only 
25% of prostate cancer patients are able to live 5 years subsequent to their diagnosis of 
bone metastasis (Roodman, 2004). Bone metastasis phenotype in prostate cancer patients 
results in significant morbidity and mortality due to extreme pain, pathologic fractures 
and other skeletal related complications including spinal cord compression. These 
patients have a mean survival period of 9 months to one year (Cheville et al., 2002) and 
currently, there is no available therapy to treat the bone metastases. In the coming years, 
due to the increase in the average life expectancy, it is expected that the incidence and 
mortality of prostate cancer will continue to increase.  
The metastatic process consists of a number of sequential steps including loss of 
polarity, epithelial structure disorganization, disruption of the basement membrane  
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leading to degradation of extracellular matrix, invasion of blood and lymph vessels, 
escape of the tumor cells into blood and lymph vessels or extravasation, establishment of 
secondary foci by the escaped tumor cells and angiogenesis. 
Creating and characterizing mouse models that better mimic the progression in 
human prostate cancer is a powerful tool to study and delineate the various steps in tumor 
progression. Most of the currently available mouse models of prostate cancer successfully 
recapitulate the early steps of tumor progression in the primary site but fail to metastasize 
to other organs especially to the bone. Amongst the existing ones, transgenic models that 
are created by dysregulating a gene that is widely known to be altered in human prostate 
cancer are considered to be more reflective of the human disease. This is in contrast to 
transgenic mouse models that overexpress the small t and large T antigens that despite the 
phenotype they produce, are considered to have little physiological significance.  
Hepsin is consistently up-regulated in more than 90% of human prostate tumors, 
including one report which provided evidence of increases of 34-fold when compared to 
non-tumor controls (Landers et al., 2005; Stephan et al., 2004). Additionally, hepsin 
expression levels have been shown to positively correlate with disease progression in 
human prostate cancer (Chen et al., 2003; Stamey et al., 2001; Xuan et al., 2006). A 
number of well characterized models for mouse prostate adenocarcinoma exist; however, 
in most of these models hepsin levels are low or nonexistent (Hu et al., 2002; Wu and 
Parry, 2007). Transgenic mice expressing hepsin under the control of the prostate specific 
probasin promoter do not display changes in cell proliferation or differentiation but do 
show a disorganization of the basement membrane (Klezovitch et al., 2004). Further, 
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when PB-hepsin transgenic mice are crossed with a transgenic line  expressing the SV40 
Large-T antigen in the prostate (LPB-Tag 12-7f line), the resulting bigenic offspring 
displayed dramatic acceleration in tumor progression and metastasis to the bone making 
it the only transgenic prostate cancer mouse model displaying reproducible bone 
metastasis (Klezovitch et al., 2004). These studies indicated that hepsin plays a key role 
in prostate cancer progression, as opposed to the initiation of prostate tumorigenesis.  
However, previously developed LPB-Tag/PB-hepsin mice develop invasive 
adenocarcinoma as well as neuroendocrine cancer in the primary tumor. Further, the 
metastatic lesions in these LPB-Tag/PB-hepsin mice were neuroendocrine in nature.  In 
human prostate cancer, the vast majority of primary tumors are adenocarcinomas 
(Grignon, 2004). However, in several human prostate tumors, following androgen 
deprivation therapy, the adenocarcinoma progresses to more aggressive androgen 
independent tumors that develop varying degrees of neuroendocrine differentiation.  
Primary human prostate tumors that are neuroendocrine in nature are extremely rare and 
akin to NE cancers in other tissues are highly aggressive (Azumi et al., 1984; Capella et 
al., 1995; Capella et al., 1981; Cohen et al., 1990; di Sant'Agnese and de Mesy Jensen, 
1984; Ghali and Garcia, 1984; Trias et al., 2001). Therefore, a more desirable mouse 
model for prostate cancer would incorporate the predominant features of human prostate 
cancer including reliable and faster progression to invasive adenocarcinoma, absence of 
neuroendocrine differentiation, and development of adenocarcinoma metastases to the 
bone. In order to directly test the role of increased hepsin expression in prostate cancer 
progression, we introduced high levels of hepsin expression into the prostate of the Hi-
myc mouse model of prostate adenocarcinoma. This resulting hepsin/myc bigenic mouse 
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model showed that the increased expression of hepsin results in earlier development of 
prostate adenocarcinoma, and eventually a higher grade tumor when compared to tumors 
derived from the myc mice.  
The myc protooncogene has been shown to cause increased cell proliferation in 
multiple studies. Several reports have demonstrated increased myc copy number in up to 
30% of human prostate tumors (Fleming et al., 1986; Jenkins et al., 1997; Nesbit et al., 
1999; Qian et al., 1997; Sato et al., 1999). The myc transgenic mouse model utilizing the 
prostate specific probasin promoter displays a reliable penetrance to HGPIN lesions and 
progression to invasive adenocarcinoma in 6 months (Ellwood-Yen et al., 2003). The 
myc transgenic mice develop PIN with progression to an adenocarcinoma that is devoid 
of any neuroendocrine differentiation. However, the myc model of prostate cancer 
spontaneously expresses low hepsin levels suggesting that progression of the cancer in 
this model is paralleling events that occur in human prostate cancer. However, these low 
levels of hepsin expression may not accurately reflect the physiological consequences 
that the widespread over-expression of hepsin causes in human prostate tumors.  
To investigate the effect of hepsin over-expression in a mouse model of prostate 
adenocarcinoma, we generated the hepsin/myc bigenic mouse. Hepsin up-regulation in 
the myc model accelerates the incidence of adenocarcinoma from 6 months to 4.5 
months. As mice were aged up to 17 months, the prostate tumors of hepsin/myc mice 
displayed a higher pathological grade of cancer when compared to age matched mice 
expressing myc alone in the prostate. This finding further supports an important role for 
increased hepsin expression and activity during progression of adenocarcinoma. Also, the 
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tumors in our bigenic mice did not develop features of neuroendocrine differentiation and 
were negative for synaptophysin, a neuroendocrine marker. Further, we found that 
endogenous hepsin levels, although low when compared to the probasin targeted hepsin, 
were present in the myc mice and increased significantly (p <0.05) as the myc tumors 
progressed to 12, 15 and 17 months when compared with the 6 month myc tumor.  This 
finding demonstrates that expression of hepsin in the myc tumors occurs spontaneously 
and reflects similar events seen during the progression of human prostate cancer.  
Another important step that has been documented in the progression of human 
prostate cancer is loss of Laminin-332, a component of the basement membrane 
(Calaluce et al., 2001; Davis et al., 2001; Hao et al., 2001; Nagle, 2004). We therefore 
wanted to investigate if the increased aggressiveness in hepsin/myc tumors is associated 
with the loss of Laminin-332. Interestingly, we found that compared with age matched 
myc alone tumor, the 12 month hepsin/myc tumor tissue displayed increased degradation 
of Laminin-332. Our data is consistent with a recent report that shows that hepsin 
proteolytically cleaves the beta 3 chain of Laminin-332 in vitro and that there is enhanced 
in vitro migration of prostate cancer cells due to this cleavage  event (Tripathi et al., 
2008). Although only a few other substrates for hepsin including blood clotting factors, 
pro-urokinase and pro-hepatocyte growth factor have been identified, hepsin targets must 
play an important role in the progression of prostate cancer (Kazama et al., 1995; 
Kirchhofer et al., 2005; Moran et al., 2006). We suggest that the cleavage of Laminin-332 
is an important step during progression to higher grade cancer.  Since the degradation of 
Laminin-332 occurs as human prostate cancer progresses, our data would suggest that the 
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elevated levels of hepsin is responsible for the loss of Laminin-332 during progression of 
human prostate cancer.   
The data showing that disorganization of the basement membrane in transgenic 
mice over-expressing hepsin combined with data showing that hepsin cleaves Laminin-
332 strongly indicates that hepsin may be directly involved in the disruption of the 
basement membrane through degradation of the extracellular matrix proteins (Tripathi et 
al., 2008). Further, interestingly, since hepsin expression is decreased in metastatic 
lesions (Dhanasekaran et al., 2001) suggests that there is no positive selection for the 
expression of hepsin at the stage when tumor cells are trying to re-establish themselves at 
distant sites. A plausible meachanism of action of hepsin is that while its expression and 
proteolytic activity  is necessary during the initial stages of tumorigenesis to disrupt the 
basement membrane and initiate invasion, this activity is counter-productive when the 
cells are trying to establish themselves at distant sites since the cells at this stage are 
attempting to adhere to the extracellular matrix. In agreement, metastasis derived prostate 
cancer cell lines do not express hepsin and overexpression of hepsin in these cells results 
in retardation of cell growth and increase in apoptosis (Srikantan et al., 2002). It is 
possible to hypothesize that hepsin along with other proteloytic enzymes may play 
different roles at the different steps of progression of cancer and metastasis. In contrast to 
artificial systems of tissue culture or in systems where tumor cells are injected into 
immunocompromised mice, transgenic model systems represent a more holistic approach 
of looking at the tumor progression from normal tissue to PIN to adenocarcinoma to 
metastasis. Such an approach helps dissect the entire sequence of events leading to 
metastasis. 
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The changes in the role of hepsin during the progression of prostate cancer 
suggest that different treatments are required to target the different stages in the 
progression of prostate cancer. Further, it would suggest that the approach of targeting a 
particular protein for at an early step of adenocarcinoma such as the initial invasion and 
escape of cells, may not be a suitable approach while targeting the late stage when the 
cancer cells that form metastatic lesions at distant organs. In other words, drugs that 
target the initial stages of the tumor would need to be discontinued and other drugs that 
target the more advanced tumors would need to be administered. Otherwise the drug of 
the former type may actually promote the establishment of the tumor cells in distant 
organs. In the future, strategies to treat cancer may include the precisely monitoring of 
the tumor stage and administering treatment depending on that stage. In keeping with the 
data on hepsin, the potential use of the inhibitors of hepsin may be particularly suited 
during watchful waiting which is often clinically chosen for patients who have low grade 
prostate cancer. If the potential use of hepsin inhibitor can slow down the progression of 
prostate cancer in its early stage, it may hypothetically be able to push the onset of 
advance prostate cancer and extend the average life span, thus eliminating prostate cancer 
as a cause of disease and death in men. 
However, unlike the LPB-Tag/PB-hepsin mice, no metastasis was detected in 
either myc alone or hepsin/myc bigenic mice. It has been argued that while hepsin may 
play an important role in the primary tumors by degrading basement membrane 
molecules, the low levels of hepsin in the metastatic lesions and metastasis-derived 
human prostate cell lines indicates a paradoxical nature of hepsin as a metastasis 
promoting gene. It is plausible to hypothesize that hepsin may play varying roles 
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depending on the prostate tumor type (adenocarcinoma or neuroendocrine tumor) and 
also depending on its expression at specific time points in the tumor progression cascade. 
We speculate that the absence of metastasis in this model is linked to the relatively less 
aggressive adenocarcinoma that occurs in the myc mice as compared to the LPB-Tag/PB-
hepsin mice that develop aggressive neuroendocrine cancers.  This data suggests that 
hepsin expression in the tumor is not sufficient to induce metastasis from the slowly 
developing adenocarcinoma of the myc mouse prostate; however, hepsin expression does 
cause adenocarcinoma to appear earlier and tumor grade to increase at a faster rate than 
when myc alone is expressed in the mouse prostate.  
Our hepsin/myc model develops cancer as early as 4.5 months (Fig 25) and only 
the knock out (KO) of Pten in the prostate and the TRAMP models develop cancer at 
such an early age (Greenberg et al., 1995; Wang et al., 2003). However, TRAMP mice 
develop neuroendocrine cancer rather than adenocarcinoma (Chiaverotti et al., 2008). 
Both the hepsin/myc and Pten models develop primary tumors that are adenocarcinoma. 
However, prostates of Pten KO mice have limited adenocarcinoma cells that show 
neuroendocrine differentiation that further increased in castrated mice (Liao et al., 2007). 
In our hepsin/myc model, no neuroendocrine differentiation occurs in either intact or 
castrated mice.  
In summary, our hepsin/myc model shows rapid progression (Fig 25) to prostate 
adenocarcinoma and mimics multiple features of human prostate cancer progression by 
the over-expression of hepsin as well as myc and the loss of Laminin-332. The use of this 
new bigenic model will aid in the identification of novel hepsin substrates that contribute 
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to prostate adenocarcinoma progression and more importantly aid in the testing of 
compounds that inhibit hepsin activity, thus identifying compounds for prostate cancer 
therapy in humans. 
 
 
 
Figure 25: Cartoon depicting the progression of adenocarcinoma in the myc and the 
hepsin/myc mice.  
 
The myc mice develop PIN at 3 months and adenocarcinoma by 6 months. In contrast, 
the hepsin/myc bigenic mice develop PIN lesions at 3 months but progress to the 
adenocarcinoma step at 4.5 months. Further, the hepsin/myc mice develop a higher grade 
of adenocarcinoma at higher ages compared with the myc mice.  
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The final step in the metastatic cascade is the colonization and growth of the 
tumor cells in the bone and the various physiological complications associated with it in 
cancer patients. Since the establishment of bone metastases is dependent on the bone 
microenvironment, understanding the cellular interaction between prostate carcinoma 
cells and the bone microenvironment may provide a critical insight about the origin and 
maintenance of prostate cancer bone lesions. It has been proposed that the homing of 
prostate cancer cells in the bone is a non-random process that involves multiple steps. 
Further, it is now known that a vicious cycle is created between prostate cancer cells and 
the bone microenvironment that is mediated by factors secreted by the tumor cells and 
that the bone plays an important role in supporting and sustaining these bone metastases. 
Although, human prostate cancer produces bone lesions that are predominantly 
osteoblastic in nature, but osteoclastic resorption has been shown to be an integral part of 
skeletal metastases in this cancer (Basaria et al., 2002; Clarke et al., 1992). It has been 
shown that prostate cancer patients with bone metastases have higher levels of bone 
resorption markers as compared to patients without bone metastases (Maeda et al., 1997).  
Further, recent clinical trials have indicated that treatment strategies that block 
osteoclastic bone resorption decrease the skeletal related complications in prostate cancer 
patients (Oades et al., 2002). But intriguingly, the inhibition of osteoclast activity in a 
murine model did not lead to a decrease in the development of osteoblastic metastasis 
(Lee et al., 2002). It is therefore not clear whether bone destruction takes place before the 
development of osteoblastic metastases or if it is caused by increased bone formation. 
Interestingly, Yi et al working with an animal model of osteoblastic bone metastasis have 
reported that increased bone formation is preceded by an initial phase of bone resorption, 
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thereby suggesting that the activation of osteoclasts may play an important role in the 
development of osteoblastic metastases (Yi et al., 2002). The established cell lines of 
human prostate cancer when injected in bone microenvironment of immunocompromised 
mice produce both osteoblastic and osteolytic phenotypes (Corey et al., 2002; Zhau et al., 
1996). 
One important area of prostate cancer research that needs particular attention is 
the development of relevant animal models that reflect or mimic the final step in human 
prostate cancer progression, i.e. the manifestation of skeletal metastases. Such an 
understanding of the interactions between prostate cancer cells and the bone 
microenvironment will lead to novel approaches towards the discovery of selective 
therapeutic targets for the treatment of the skeletal metastases. A large number of 
transgenic mouse models that mimic prostate cancer have been created; although all these 
models have contributed greatly to our understanding of the multistep nature of prostate 
cancer, however, spontaneous bone metastases from these models are rare. In order to 
recapitulate human prostate cancer metastasis, the tumor cells in a transgenic mouse 
model must be able to disseminate from the primary tumor, metastasize to bone and 
produce an osteoblastic reaction in the bone. Intriguingly, very few of the experimental 
mouse models for mouse prostate cancer mimic the bone metastasis step that is so 
widespread in human prostate cancer. Experimental models of bone metastasis therefore 
consist of injecting cancer cells or tissue orthotopically, intracardially, intravenously (via 
the tail vein) or directly intraosseously into immunocompromised mice. While the 
intrafemoral/intratibial injection of cancer cells is not considered an appropriate 
technique to study the early rate-limiting steps of the metastatic cascade, the technique 
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however provides a powerful tool to model the interactions between the cancer cells and 
the bone microenvironment. 
A number of factors are known to drive the vicious cycle between prostate 
carcinoma cells and bone cells. Cancer cells interact and participate with the bone cells to 
induce osteoclasts or osteoblasts, thereby creating a metabolic imbalance between the 
number of osteoblasts and osteoclasts. This imbalance may push the bone equilibrium 
towards an osteoblastic process as in human prostate cancer bone metastases. It has been 
proposed that cancer cells undergo phenotypic changes that allow them to form bone and 
this phenomenon has been referred to as “osteomimicry” (Koeneman et al., 1999). This 
process allows cancer cells to survive and proliferate in the bone microenvironment by 
utilizing the abundance of growth factors and extracellular matrix molecules found in the 
bone, thereby creating a vicious cycle. Prostate cancer cells that have successfully 
colonized the bone frequently secrete osteoblast promoting factors including BMPs, Wnt-
family ligands, endothelin-1 (ET-1) and PDGF. Guise proposed that this vicious cycle 
also involves transforming growth factor β that is produced by the bone cells, that 
promotes the tumor cells to produce parathyroid hormone-related protein (PTHrP), which 
in turn promotes bone turnover by fostering osteolysis of the bone (Guise, 
2000).Therefore, a vicious cycle of bone turnover and tumor cell-promoted osteolytic 
response is set forth since rapid production of bone stimulates the release of TGF-β that 
in turn promotes the release of PTHrP by tumor cells. It is known that this vicious cycle 
between TGF-β and PTHrP plays a role in the osteolytic metastases of breast carcinoma 
and it is possible that the same mechanism may be operative in some prostate carcinoma 
cells.  In addition to TGF-β and PTHrP, a number of other molecules may play a role in 
108 
 
the vicious cycle between tumor cells and bone microenvironment. There is evidence that 
endothelin-1 (ET-1), a prominent cytokine produced by tumor cells may play a role in the 
osteoblastic reaction produced by prostate cancer cells that get lodged in the bone 
(Nelson and Carducci, 2000). It has been reported that ET-1 and its receptor ET-A may 
play a role in the osteoblastic phenotype by increased production of interleukin 1β (IL-
1β), TGF-β and TNF-α. Further, it is known that increased synthesis of TGF-β, 
endothelial growth factor and IL-1α in turn up regulates ET-1, thus causing the imbalance 
of growth factors and cytokines in the bone microenvironment. It is believed that such 
mechanisms that cause increase in the production of growth factors and cytokines may 
play a role in the survival and growth of prostate cancer cells in the bone (Granchi et al., 
2001; Le Brun et al., 1999).  
Bone morphogenic proteins (BMPs) are a family of growth factors that belong to 
the TGF-β superfamily and are known to play a role in the stimulation of bone synthesis 
by prostate cancer cells (Hogan, 1996). The BMPs initiate downstream signaling through 
2 two types of serine/threonine transmembrane receptor kinases, type I and type II. BMPs 
bind the type II receptor which in turn activates the type I receptor. The type I receptor 
activates members of the SMAD family of proteins, particularly SMAD 1,5 and 8; these 
SMADS interact with SMAD 4 that translocates to the nucleus and leads to the activation 
of the target genes. BMP-2, -3, -4 and -6 have been reported in normal and cancerous 
prostate tissue (Autzen et al., 1998; Harris et al., 1994b) and BMP-4, -6 and -7 were 
detected in prostate skeletal metastases (Autzen et al., 1998; Thomas and Hamdy, 2000). 
Further, BMP receptors have been reported to be expressed in prostate tissue and cell 
lines (Brubaker et al., 2004; Ide et al., 1997; Kim et al., 2000). These studies suggest that 
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BMPs expressed by prostate tumor and bone may play a direct effect on prostate cancer 
cells. It has been shown that BMP2 inhibits LNCaP cell growth by increased levels of 
p21 and causes further downstream inactivation of Rb protein (Brubaker et al., 2004). In 
PC3 cells, BMP2 treatment increased p21 levels although proliferation was not affected. 
Further, it was also reported that in PC3 cells, BMP2 treatment increased the level of 
OPG which is a decoy receptor for the receptor activator for NF-κB, a molecule that 
stimulates osteolysis(Brubaker et al., 2004). However, since PC3 cells are strongly 
osteolytic, the remodeling pathways involving OPG in PC3 cells may well be masked by 
factors that stimulate bone resorption such as matrix metalloproteases (Nemeth et al., 
2002), urokinase plasminogen activator (Yoshida et al., 1994), RANKL (Brown et al., 
2001) and PTHrP (Iwamura et al., 1994) that are expressed by PC3 cells. 
Since our hepsin/myc transgenic model did not develop bone metastases, we took 
the approach of studying the effect of Tbx2, a T-box transcription repressor to model the 
interactions between the bone and prostate tumor cells. We initially stumbled on Tbx2 in 
a screen for androgen regulated genes. Interestingly, Tbx2 expression was up regulated in 
LNCaP human prostate cancer cells with androgen treatment. To study the androgen 
regulation in an in vivo setting, we castrated male mice, administered androgens two 
weeks following castration and looked at Tbx2 expression. Consistent with the in vitro 
data, Tbx2 levels increased following androgen treatment in all the lobes of the rodent 
prostate as compared to the oil control. Further, Tbx2 is very highly expressed in all the 
aggressive human prostate cancer cell lines including PC3, DU145, and LAPC4 cells and 
very low in the relatively benign cell lines including RWPE1 and LNCaP cells. This 
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intrigued us since it has been reported that Tbx2 is highly expressed in human melanoma, 
pancreatic and breast cancer cell lines.  
Further, BMP2, a member of the bone morphogenic protein family that belongs to 
the TGF-beta superfamily, is also very highly expressed in the more aggressive prostate 
cancer cells. This correlation further intrigued us since BMP2 has been reported to be 
dysregulated during human prostate cancer progression and interestingly it has been 
shown previously that during development, there is a feedback and feed forward 
signaling between BMP2 and Tbx2. Further, Tbx2 has also been reported to have a 
similar feedback and feed forward regulation with sonic hedgehog signaling, a pathway 
that has also been reported to be dysregulated in human prostate cancer.  
We found that BMP2 when added in the culture medium induces Tbx2 expression 
in LAPC4 cells that are known to have the BMP2 receptor. Further, addition of BMP2 
induced Wnt 3a. This was of interest to us since the Wnt family of proteins has been 
reported to be involved in bone formation. We next took the approach of repressing 
endogenous Tbx2 in human prostate cancer cells by utilizing a dominant negative 
construct which we stably infected into human prostate cancer cell lines LAPC4, PC3 and 
DU145. In vitro cell proliferation was decreased in all three cell lines. Since BMP2 has 
been reported to mediate osteogenic effects and Tbx2 is downstream of BMP2, we were 
interested in looking at the effect of manipulating Tbx2 on the interactions between 
prostate cancer cells and the bone microenvironment. When inoculated into the intra-
tibial model, PC3 cells infected with the Tbx2 DN construct produced smaller lesions that 
were significantly less osteolytic when compared to the lesions produced by the control 
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PC3 cells. This decrease in osteolysis was seen by x-ray analysis which is semi-
quantitative technique for estimating the change in bone density. Therefore, the decrease 
in osteolytic effect was further confirmed by micro CT analysis which provides a 
quantitative measure of the change in bone density. Since BMP2 is known to signal 
downstream through the phosphorylation of SMAD 1,5,8, we looked at this SMAD and 
found that nuclear levels of phospho SMAD 1,5,8 is decreased in PC3 cells with 
dominant negative Tbx2. Further, in vitro, Tbx2 dominant negative construct decreases 
Wnt3a, Gli2 and PTHRP signaling in PC3 cells.  
In summary, we have found that blocking endogenous Tbx2 levels reduces tumor 
and osteolytic burden in PC3 human prostate cancer cells. Since research in recent years 
has indicated that one of the ways to reduce the osteogenic burden of prostate tumors is 
through reducing the osteolytic activity that occurs in the background of the overall 
osteoblastic effect, blocking Tbx2 may be used as a therapeutic target in the future. 
 
Future Directions: 
Since orthotopic grafts are widely considered to have a greater physiological 
relevance to the study of tumor progression as compared with kidney capsule or 
subcutaneous grafts, an alternative approach to test the effect of Tbx2 DN construct in 
PC3 cells would be to graft these cells in the anterior prostatic lobe of nude mice. PC3 
cells when grafted orthotopically into the NOD-SCID mice have been reported to display 
metastases to a variety of soft tissues but bone metastases have not been reported. 
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Interestingly however, when fragments from a subcutaneous xenograft were used for an 
orthotopic graft in the prostate of nude mice, the primary prostatic tumor resulted in  
extensive skeletal metastases as well as soft tissue metastases (Yang et al., 1999). 
Also, although tibial inoculation of tumor cells allows us to study the tumor cell–
bone microenvironment interactions, it is not a good model for the study of metastasis. 
Therefore, in order to study the metastatic ability of cells, an elegant alternative is the 
intracardiac injection of cells in nude mice. Following intracardiac injection, luciferase 
tagged PC3 cells have been shown to colonize the lumbar spine, teeth and hind limbs and 
this progression was shown in a quantitative fashion facilitated by the presence of the 
luciferase in the cells (Kalikin et al., 2003). 
  An alternate method of testing the genetic manipulation of Tbx2 in prostate 
cancer cells would be to over-express Tbx2 in human prostate cancer cells that express 
low Tbx2 levels. LNCaP cells are relatively benign human prostate cancer cells that do 
not form aggressive grafts when placed under the kidney capsule and express low levels 
of endogenous Tbx2. Further, LNCaP cells when grafted into mouse tibia do not show 
significant growth. Therefore a good approach of testing the effects of Tbx2 would be to 
stably overexpress Tbx2 in LNCaP cells and perform under the kidney capsule, 
subcutaneously, orthotopic, tibial inoculation and by intracardiac injection experiments of 
LNCaP cells over-expressing Tbx2 compared to control LNCaP cells. The presence of 
GFP in the cells would enable imaging the tumor at the sites of the grafts, at potential 
metastatic sites, and by in the tumor sections by immunohistochemical analyses. Based 
upon my data, it would be expected that overexpression of Tbx2 in LNCaP cells would 
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make these cells more aggressive when placed under the kidney capsule, subcutaneously, 
orthotopic, tibial inoculation and by intracardiac injection experiments. The kidney 
capsule grafts are a good model to study invasion at the interface of the tumor and the 
kidney surface while the other grafting site would test the ability to grow in specific 
microenvironments. Intracardiac injection would test the role of Tbx2 to cause a tumor to 
colonize other tissues. Further, my data would suggest that the overexpression of Tbx2 
would make LNCaP cells form osteoblastic lesions when placed in the bone 
microenvironment or to spread to that site when injected intracardially in mice.  
Following the studies with LNCaP cells overexpressing Tbx2, an elegant idea 
would be the creation of a transgenic mouse model overexpressing Tbx2 in the mouse 
prostate. Tbx2 expression can be targeted specifically to the prostatic epithelial cells 
utilizing the prostate specific probasin promoter. It would be expected that 
overexpression of Tbx2 in the prostatic cells would lead to neoplastic transformation of 
the cells resulting in adenocarcinoma. Further, the Tbx2 transgenic mouse could be 
crossed with another mouse model that develops prostate cancer like the Pten conditional 
KO mouse or the PB-Hi-Myc mouse to look for further progression and even metastasis 
to the bone.  
This research supports a fundamental role for Tbx2 during the progression of 
prostate cancer to metastatic sites.  Further studies on the pathways that Tbx2 controls 
during the metastatic process can result in the identification of new targets genes for 
therapeutic intervention.   
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